US20070261126A1 - Methods and sequences to suppress primate huntington gene expression in vivo - Google Patents
Methods and sequences to suppress primate huntington gene expression in vivo Download PDFInfo
- Publication number
- US20070261126A1 US20070261126A1 US11/501,634 US50163406A US2007261126A1 US 20070261126 A1 US20070261126 A1 US 20070261126A1 US 50163406 A US50163406 A US 50163406A US 2007261126 A1 US2007261126 A1 US 2007261126A1
- Authority
- US
- United States
- Prior art keywords
- nucleic acid
- seq
- expression
- strand
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 246
- 238000000034 method Methods 0.000 title claims abstract description 65
- 241000288906 Primates Species 0.000 title claims abstract description 10
- 238000001727 in vivo Methods 0.000 title description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 56
- 241000282414 Homo sapiens Species 0.000 claims abstract description 45
- 241000282560 Macaca mulatta Species 0.000 claims abstract description 45
- 150000007523 nucleic acids Chemical class 0.000 claims description 200
- 125000003729 nucleotide group Chemical group 0.000 claims description 160
- 239000002773 nucleotide Substances 0.000 claims description 159
- 108020004707 nucleic acids Proteins 0.000 claims description 156
- 102000039446 nucleic acids Human genes 0.000 claims description 156
- 239000013598 vector Substances 0.000 claims description 114
- 210000004027 cell Anatomy 0.000 claims description 99
- 230000000295 complement effect Effects 0.000 claims description 54
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 210000002637 putamen Anatomy 0.000 claims description 28
- 210000004556 brain Anatomy 0.000 claims description 21
- 230000003612 virological effect Effects 0.000 claims description 11
- 239000013603 viral vector Substances 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 231100000433 cytotoxic Toxicity 0.000 claims description 8
- 230000001472 cytotoxic effect Effects 0.000 claims description 8
- 230000008488 polyadenylation Effects 0.000 claims description 8
- 208000023105 Huntington disease Diseases 0.000 claims description 7
- 241001529936 Murinae Species 0.000 claims description 7
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 claims description 5
- 210000001159 caudate nucleus Anatomy 0.000 claims description 5
- 108020003519 protein disulfide isomerase Proteins 0.000 claims description 5
- 238000009825 accumulation Methods 0.000 claims description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 4
- 108010056891 Calnexin Proteins 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 230000006742 locomotor activity Effects 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 101710177611 DNA polymerase II large subunit Proteins 0.000 claims description 2
- 101710184669 DNA polymerase II small subunit Proteins 0.000 claims description 2
- 241000991587 Enterovirus C Species 0.000 claims description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 102000034342 Calnexin Human genes 0.000 claims 1
- 101001024566 Homo sapiens Ecto-ADP-ribosyltransferase 4 Proteins 0.000 claims 1
- 210000001577 neostriatum Anatomy 0.000 claims 1
- 102000016252 Huntingtin Human genes 0.000 abstract description 37
- 108050004784 Huntingtin Proteins 0.000 abstract description 37
- 108020004999 messenger RNA Proteins 0.000 abstract description 36
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 230000008506 pathogenesis Effects 0.000 abstract description 6
- 230000007253 cellular alteration Effects 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 230000006738 locomotor deficit Effects 0.000 abstract 1
- 101150113725 hd gene Proteins 0.000 description 34
- 230000001629 suppression Effects 0.000 description 34
- 239000013612 plasmid Substances 0.000 description 30
- 108091028043 Nucleic acid sequence Proteins 0.000 description 29
- 241000282693 Cercopithecidae Species 0.000 description 25
- 239000005090 green fluorescent protein Substances 0.000 description 23
- 101001030705 Homo sapiens Huntingtin Proteins 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 16
- 230000009368 gene silencing by RNA Effects 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 14
- 102000054185 human HTT Human genes 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000003753 real-time PCR Methods 0.000 description 13
- 238000001890 transfection Methods 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 239000004055 small Interfering RNA Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000013607 AAV vector Substances 0.000 description 10
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 10
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 108091027967 Small hairpin RNA Proteins 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000001001 laser micro-dissection Methods 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 241000702421 Dependoparvovirus Species 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 102000007469 Actins Human genes 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 108091030071 RNAI Proteins 0.000 description 5
- 230000001149 cognitive effect Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 244000089409 Erythrina poeppigiana Species 0.000 description 4
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 102000014450 RNA Polymerase III Human genes 0.000 description 4
- 108010078067 RNA Polymerase III Proteins 0.000 description 4
- 235000009776 Rathbunia alamosensis Nutrition 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 108091092328 cellular RNA Proteins 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- 101150054147 sina gene Proteins 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 108091081021 Sense strand Proteins 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000001697 htt accumulation Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 108091053008 miR-23 stem-loop Proteins 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008925 spontaneous activity Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100021868 Calnexin Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 2
- 241000283923 Marmota monax Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000211 autoradiogram Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- SPTYHKZRPFATHJ-HYZXJONISA-N dT6 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 SPTYHKZRPFATHJ-HYZXJONISA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 241000945470 Arcturus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010009696 Clumsiness Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100028652 Gamma-enolase Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
- 208000015592 Involuntary movements Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- -1 cationic lipid Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 102000047486 human GAPDH Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 102000023888 sequence-specific DNA binding proteins Human genes 0.000 description 1
- 108091008420 sequence-specific DNA binding proteins Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Definitions
- the present invention relates to inhibitory nucleic acid molecules that suppress the expression of the Huntington's disease gene in primates, including rhesus monkeys ( Macaca mulatta ) and humans ( Homo sapiens ), and methods of use thereof.
- Huntington's disease is a neurodegenerative brain disorder with a juvenile or adult onset. It slowly destroys an affected individual's ability to walk, think, talk and reason. Symptoms include changes in cognitive ability, such as impaired short-term memory and a decreased ability to concentrate; changes in mood, such as the development of mood swings, depression and irritability; and changes in coordination and physical movement such as clumsiness, involuntary movements and twitching. These symptoms gradually worsen until HD patients die, approximately 15-20 years after the onset of the disease.
- HD is inherited as an autosomal dominant trait. This inheritance feature means that every individual who inherits a mutated (expanded) HD gene from either parent will develop the disease.
- the HD gene encodes for a protein called “huntingtin” (also known as “htt”).
- huntingtin also known as “htt”.
- the exact function of huntingtin is not known.
- the expression of a mutant, expanded huntingtin protein is known to be the cause of HD, however.
- mRNA messenger RNA
- Ribosomes read the sequence of the mRNA and create the protein for which it encodes. This process of new protein synthesis is known as translation. A variety of factors affect the rate and efficiency of protein translation.
- the intrinsic stability of the mRNA itself is the intrinsic stability of the mRNA itself. If the mRNA is degraded quickly within the cell (such as before it reaches a ribosome), it is unable to serve as a template for new protein translation, thus reducing the cell's ability to create the protein for which it encoded.
- RNA interference is, in fact, a naturally-occurring mechanism for suppressing gene expression and subsequent protein translation. RNA interference suppresses protein translation by either degrading the mRNA before it can be translated or by binding the mRNA and directly preventing its translation. This naturally-occurring mechanism of RNA interference can also be artificially induced to occur in cells.
- RNA interference can be achieved by introducing into cells short, double-stranded nucleic acid oligonucleotides corresponding to the mRNA for the gene to be suppressed, or by introducing into cells a sequence of DNA that encodes for a short, hairpin transcript of nucleic acids that folds back upon itself and forms a short, double-stranded nucleic acid oligonucleotide following further processing in the cell.
- This technology provides a means to suppress the expression of huntingtin in cells.
- the suppression of huntingtin in cells can be useful in the study of HD pathogenesis. Suppressing huntingtin in a patient also could prevent or alleviate the symptoms of HD.
- RNA interference RNA interference
- Suppressing expression of the HD gene can reduce levels of huntingtin within cells. This suppression and reduction can be useful in the study of HD pathogenesis. This suppression and reduction also can be useful in the prevention and treatment of the symptoms of HD.
- RNAi is mediated by double stranded RNA (“dsRNA”), short hairpin RNA (“shRNA”) or other nucleic acid molecules with similar characteristics. These nucleic acid molecules are processed or cut into smaller pieces by cellular enzymes including Dicer and Drosha.
- the smaller fragments of the nucleic acid molecules can then be taken up by a protein complex called the RNA-induced silencing complex (“RISC complex”) that mediates degradation of mRNAs.
- RISC complex RNA-induced silencing complex
- the RISC complex will degrade mRNA that complementarily base pairs with the nucleic acid molecules it has taken up. In this manner, the mRNA is specifically destroyed, thus preventing the protein for which the mRNA encoded from being made.
- RNAi RNAi RNAi RNAi RNAi .
- nucleic acid sequences and molecules that are homologous to primate HD mRNA sequences are introduced into cells to suppress expression of huntingtin protein.
- nucleic acid sequences and molecules specifically suppress the expression of mRNA sequences that encode for primate huntingtin protein, including rhesus monkey and human huntingtin. Suppressing expression of this protein can be useful in the study of HD pathogenesis. This suppression also could be useful in the prevention and/or treatment of HD.
- the invention includes a nucleic acid molecule comprising a first strand and a second strand wherein the first strand comprises a nucleotide sequence and wherein the second strand comprises the reverse complement of said first strand and wherein the nucleic acid molecule suppresses the expression of both Macaca mulatta and Homo sapiens mRNA sequences that encode for huntingtin.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 1 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 2 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 3 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 4 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 5 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 6 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 7 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 8 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 9 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 10 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 11 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 12 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 13 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 14 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 15 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 27 contiguous nucleotides encoded by SEQ ID NO: 9 and wherein the second strand is complementary to at least 23 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 27 contiguous nucleotides encoded by SEQ ID NO: 10 and wherein the second strand is complementary to at least 23 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 27 contiguous nucleotides encoded by SEQ ID NO: 11 and wherein the second strand is complementary to at least 23 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 27 contiguous nucleotides encoded by SEQ ID NO: 12 and wherein the second strand is complementary to at least 23 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 27 contiguous nucleotides encoded by SEQ ID NO: 13 and wherein the second strand is complementary to at least 23 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 27 contiguous nucleotides encoded by SEQ ID NO: 14 and wherein the second strand is complementary to at least 23 contiguous nucleotides of the first strand.
- the invention in another embodiment, includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 27 contiguous nucleotides encoded by SEQ ID NO: 15 and wherein the second strand is complementary to at least 23 contiguous nucleotides of the first strand.
- the nucleic acid duplex is between 19 and 30 base pairs in length.
- the first and/or second strand of the nucleic acid duplex comprises an overhang region. In another embodiment of the present invention, the first and/or second strand of the nucleic acid duplex comprises a 3′ overhang region, a 5′ overhang region, or both 3′ and 5′ overhang regions. In another embodiment of the present invention, the first and/or second strand of the nucleic acid duplex comprises an overhang region that is from approximately 1 to approximately 10 nucleotides in length.
- the first and second strand of the nucleic acid duplex are operably linked by means of a nucleic acid loop strand that forms a hairpin structure comprising a duplex structure and a loop structure.
- the first and second strand of the nucleic acid duplex are operably linked by means of a nucleic acid loop that contains from 4 to 10 nucleotides.
- the invention includes an expression cassette.
- the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 1.
- the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 2.
- the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 3.
- the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 4.
- the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 5.
- the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 6.
- the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 7.
- the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 8. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 9. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 10. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 11. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 12. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 13. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 14. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 15.
- the expression cassette also comprises a promoter. In another embodiment of the present invention, the expression cassette comprises a regulatable promoter. In another embodiment of the present invention, the expression cassette comprises a constitutive promoter. In another embodiment of the present invention, the expression cassette comprises a promoter that is a cytomegalovirus (“CMV”) promoter. In another embodiment of the present invention, the expression cassette comprises a promoter that is a Rous sarcoma virus (“RSV”) promoter. In another embodiment of the present invention, the expression cassette comprises a promoter utilized by RNA polymerase II. In another embodiment of the present invention, the expression cassette comprises a promoter utilized by RNA polymerase III.
- CMV cytomegalovirus
- RSV Rous sarcoma virus
- the expression cassette comprises a polyadenylation signal. In another embodiment of the present invention, the expression cassette comprises a polyadenylation signal that is a synthetic minimal polyadenylation signal. In another embodiment of the present invention, the expression cassette comprises a marker gene.
- the invention includes a vector comprising one or more of the expression cassettes previously described.
- the vector comprises a first and a second expression cassette.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 1 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 1.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 2 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 2.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 4 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 4.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 5 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 5.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 6 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 6.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 7 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 7.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 9 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 9.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 10 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 10.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 11 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 11.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 12 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 12.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 14 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 14.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 15 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 15.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 9 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 23 contiguous nucleotides of SEQ ID. NO. 9.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 10 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 23 contiguous nucleotides of SEQ ID. NO. 10.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 12 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 23 contiguous nucleotides of SEQ ID. NO. 12.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 13 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 23 contiguous nucleotides of SEQ ID. NO. 13.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 14 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 23 contiguous nucleotides of SEQ ID. NO. 14.
- the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 15 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 23 contiguous nucleotides of SEQ ID. NO. 15.
- the vector is a viral vector. In another embodiment of the present invention, the vector is an adenoviral virus vector. In another embodiment of the present invention, the vector is a lentiviral virus vector. In another embodiment of the present invention, the vector is an adeno-associated viral (AAV) virus vector. In another embodiment of the present invention, the vector is a poliovirus vector. In another embodiment of the present invention, the vector is a herpes simplex virus vector. In another embodiment of the present invention, the vector is a feline immunodeficiency virus vector. In another embodiment of the present invention, the vector is a murine Maloney-based viral vector.
- AAV adeno-associated viral
- the vector comprises a promoter. In another embodiment of the present invention, the vector comprises an inducible promoter.
- the invention includes a cell comprising a previously-described expression cassette.
- the cell is a mammalian cell.
- Another embodiment of the present invention includes a non-human mammal comprising a previously-described expression cassette.
- the embodiments of the present invention also include methods.
- One method of the present invention includes a method of suppressing the accumulation of huntingtin in a cell comprising introducing a previously-described nucleic acid duplex into the cell in an amount sufficient to suppress accumulation of huntingtin in the cell.
- accumulation of huntingtin is suppressed by at least 10%.
- Another method of the present invention includes a method of preventing cytotoxic effects of mutant huntingtin in a cell comprising introducing a previously-described nucleic acid duplex into the cell in an amount sufficient to suppress accumulation of the mutant huntingtin so that the nucleic acid duplex prevents cytotoxic effects of mutant huntingtin in the cell.
- Another method of the present invention includes a method of inhibiting expression of a huntingtin gene in a cell comprising introducing a previously-described nucleic acid duplex into the cell in an amount sufficient to inhibit expression of huntingtin so that the nucleic acid duplex inhibits expression of huntingtin.
- Another method of the present invention includes a method of inhibiting expression of huntingtin in Macaca mulatta and Homo sapiens comprising providing a Macaca mulatta or Homo sapiens containing a neuronal cell that contains and expresses the huntingtin gene and is susceptible to nucleic acid interference and contacting the Macaca mulatta or Homo sapiens with a previously-described nucleic acid duplex thereby inhibiting expression of the huntingtin gene.
- expression of huntingtin is inhibited by at least 10%.
- Another method of the present invention includes a method of preventing cytotoxic effects of Huntington's disease (“HD”) in a Macaca mulatta or Homo sapiens comprising introducing a previously-described vector into a cell in an amount sufficient to suppress accumulation of a protein associated with HD, so that the resulting nucleic acid duplex prevents the cytotoxic effects of HD.
- HD Huntington's disease
- Another method of the present invention includes a method of inhibiting expression of the huntingtin gene in a Macaca mulatta or Homo sapiens comprising introducing a previously-described vector into a cell in an amount sufficient to inhibit expression of the huntingtin gene so that the resulting nucleic acid duplex inhibits expression of the huntingtin protein.
- Another method of the present invention includes a method of inhibiting expression of huntingtin in a Macaca mulatta or Homo sapiens comprising providing a Macaca mulatta or Homo sapiens containing a neuronal cell, wherein the neuronal cell contains and expresses the huntingtin gene and is susceptible to nucleic acid interference, and contacting the Macaca mulatta or Homo sapiens with a previously-described vector, thereby inhibiting expression of the huntingtin gene.
- Additional method of the present invention includes a method of preventing cytotoxic effects of Huntington's disease (“HD”) in a Macaca mulatta or Homo sapiens comprising introducing the isolated nucleic acid duplex comprising SEQ ID. NO: 1 or SEQ. ID. NO: 4 into a cell in an amount sufficient to suppress accumulation of a protein associated with HD, and wherein the nucleic acid duplex prevents cytotoxic effects of HD.
- HD Huntington's disease
- Additional method of the present invention includes a method of inhibiting expression of huntingtin in a Macaca mulatta or Homo sapiens comprising introducing the isolated nucleic acid duplex comprising SEQ ID. NO: 1 or SEQ. ID. NO: 4 into a cell in an amount sufficient to inhibit expression of huntingtin wherein said nucleic acid duplex inhibits expression of the protein associated with HD.
- the nucleic acid duplexes or vectors are administered to the intrathecal space of the spinal cord. In another embodiment of the present invention, the nucleic acid duplexes or vectors are administered to the cerebrospinal fluid in one or more of the cerebral ventricles of the brain. In another embodiment of the present invention, the nucleic acid duplexes or vectors are administered directly into the brain tissue of the cerebral cortex. In another embodiment of the methods of the present invention, the nucleic acid duplexes or vectors are administered locally to the basal ganglia. In another embodiment of the present invention, the nucleic acid duplexes or vectors are administered specifically to the caudate nucleus and the putamen.
- FIG. 1 shows a target plasmid for nucleic acid sequence characterization in HEK293 cells.
- FIG. 2 shows rhesus monkey. HD mRNA suppression by siNA sequences in vitro in HEK293 cells.
- FIG. 3 shows suppression of the endogenous rhesus HD gene at two different siNA doses in 4MBR5 cells.
- FIG. 4 shows suppression of the endogenous rhesus HD gene at five different siNA doses using both 19 and 27 nucleotide length siNAs in 4MBR5 cells.
- FIGS. 5 and 6 show suppression of the endogenous rhesus HD gene using both 19 and 27 nucleotide length siNAs in LLC-MK2 cells.
- FIG. 7 also shows suppression of the endogenous rhesus HD gene using different doses of both 19 and 27 nucleotide length siNAs in LLC-MK2 cells.
- FIGS. 8A-8D show suppression of the endogenous human HD gene at 4 different siNA doses in HeLa cells.
- FIG. 9 shows suppression of exogenous rhesus huntingtin protein expression in LLC-MK2 cells.
- FIGS. 10 and 11 show suppression of endogenous rhesus huntingtin protein expression in LLC-MK2 cells.
- FIG. 12 depicts a structure and construction of anti-HD ( FIG. 12A ) and control ( FIG. 12B ) shNA sequences (antisense strands disclosed in SEQ. ID. NOS. 28 and 29, respectively in order of appearance).
- FIGS. 13A-F show additional shNA sequences used in embodiments according to the present invention (antisense strands disclosed in SEQ. ID. NOS. 30-35, respectively in order of appearance).
- FIG. 14 shows suppression of the endogenous rhesus HD gene in LLC-MK2 cells transfected with a plasmid expressing 19 or 27 nucleotide length shNAs with EB4 or mir23 loop structures.
- FIG. 15 shows a schematic description of a pSilencer 1.0-U6 plasmid that can be used in the preparation of anti-HD and control shNA sequences.
- FIG. 16 shows an exemplary format of AAV viral constructs.
- FIG. 17 shows a plasmid used to construct pAAV vectors and to generate AAV in accordance with the present invention.
- FIGS. 18A-B show additional shNA sequences used in embodiments according to the present invention (antisense strands disclosed in SEQ. ID. NO. 36 and 37, respectively, in order of appearance).
- FIG. 19 shows suppression of exogenous rhesus HD by pAAV plasmids.
- FIG. 20 shows suppression of endogenous human HD in HeLa cells and HEK293T cells by recombinant adeno-associated virus (AAV) expressing anti-HD shNA.
- AAV adeno-associated virus
- FIGS. 21 and 22 show in vivo suppression of rhesus HD gene expression by recombinant adeno-associated virus (AAV) expressing anti-HD shNA.
- AAV adeno-associated virus
- SEQ ID NO: X refers to, in one embodiment, each number's sequence as defined in Table 1 (identified sequence). SEQ ID NO: X must also be read to encompass sequences that would hybridize with the complementary strand of a sequence set forth in SEQ ID NOS: 1-15 and reduce the particular SEQ ID NO:'s target mRNA in a cell type selected from, without limitation, HEK293 cells, 4MBR5 cells, LLC-MK2 cells, HeLA cells or any other Macaca mulatta or Homo sapien cell type.
- claimed sequences can include at least 99% sequence homology with the identified sequence; at least 98% sequence homology with the identified sequence; at least 95% sequence homology with the identified sequence; at least 90% sequence homology with the identified sequence; or at least 85% sequence homology with the identified sequence.
- nucleic acid or “nucleic acid molecules” refer to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, composed of monomers (nucleotides) containing a sugar, phosphate and a base that is either a purine or pyrimidine. Unless specifically limited, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also encompasses conservatively modified variants thereof.
- the nucleic acid molecules of the present invention can include any type of nucleic acid molecule capable of mediating RNA interference, such as, without limitation, short interfering nucleic acid (siNA), short hairpin nucleic acid (shNA), short interfering RNA (siRNA), short hairpin RNA (shRNA), micro-RNA (miRNA), and double-stranded RNA (dsRNA).
- the nucleic acid molecules of the present invention also include similar DNA sequences.
- the nucleic acid and nucleic acid molecules of the present invention can contain unmodified or modified nucleotides. Modified nucleotides refer to nucleotides which contain a modification in the chemical structure of a nucleotide base, sugar and/or phosphate.
- expression cassette means a nucleic acid sequence capable of directing expression of a particular nucleotide sequence in an appropriate host cell, with additional sequences that facilitate appropriate transcription of the nucleic acid sequence of interest.
- the expression cassette can include a promoter operably linked to the nucleotide sequence of interest that also can be operably linked to termination signals.
- the expression cassette also can include expression enhancers.
- the expression cassette including the nucleotide sequence of interest can be chimeric.
- the expression cassette also can be one that is naturally occurring but has been obtained in a recombinant form useful for heterologous expression.
- the expression of the nucleotide sequence in the expression cassette can be under the control of a constitutive promoter or of a regulatable promoter that initiates transcription only when the host cell is exposed to some particular stimulus.
- the promoter also can be specific to a particular tissue or organ or stage of development.
- promoter refers to a nucleotide sequence, usually upstream (5 prime) of the nucleotide sequence of interest, which directs and/or controls expression of the nucleotide sequence of interest by providing for recognition by RNA polymerase and other factors required for proper transcription.
- promoter includes (but is not limited to) a minimal promoter that is a short DNA sequence comprised of a TATA-box and other sequences that serve to specify the site of transcription initiation, to which regulatory elements are added for control of expression.
- promoter also refers to a nucleotide sequence that includes a minimal promoter plus regulatory elements that is capable of controlling the expression of a coding sequence or functional RNA.
- promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers.
- the term “enhancer” refers to a DNA sequence that can stimulate promoter activity and can be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue specificity of a promoter. Enhancers are capable of operating in both orientations (normal or flipped), and are capable of functioning even when moved either upstream or downstream of the promoter. Both enhancers and other upstream promoter elements bind sequence-specific DNA-binding proteins that mediate their effects. Promoters can be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even be comprised of synthetic DNA segments.
- a promoter also can contain DNA sequences that are involved in the binding of protein factors that control the effectiveness of transcription initiation in response to physiological or developmental conditions.
- Specific promoters used in accordance with the present invention can include, for example and without limitation pol II promoters (including, without limitation cytomegalovirus (“CMV”) promoters, chicken ⁇ -actin (“CBA”) promoters, Rous sarcoma virus (“RSV”) promoters and neuron-specific enolase (“NSE”) promoters).
- CMV cytomegalovirus
- CBA chicken ⁇ -actin
- RSV Rous sarcoma virus
- NSE neuron-specific enolase
- promoters used in accordance with the present invention can include, for example and without limitation, pol III promoters (including, without limitation, human H1 and human or murine U6 promoters, as well as H1 and U6 promoters engineered to be expressed in a regulated way such as described in United States Patent Application Number 2005/0064489).
- pol III promoters including, without limitation, human H1 and human or murine U6 promoters, as well as H1 and U6 promoters engineered to be expressed in a regulated way such as described in United States Patent Application Number 2005/0064489).
- vector is defined to include any virus, as well as any plasmid, cosmid, phage, binary vector or segment of nucleic acid (DNA or RNA) in double or single stranded linear or circular form that may or may not be self transmissible or mobilizable, and that can transform eukaryotic host cells either by integration into the cellular genome or by existing extrachromosomally (e.g., autonomous replicating plasmid with an origin of replication).
- the gene involved in Huntington's disease (“HD”) (IT15) is located on chromosome 4 at the end of the short arm. This gene encodes for the protein huntingtin (also known as “htt”).
- the mutation in the HD gene responsible for HD is an unstable expanded CAG trinucleotide repeat within the coding region of the gene. This mutation results in a huntingtin protein with an expanded glutamine sequence. While the normal and abnormal functions of huntingtin are not known, the presence of the mutated form of huntingtin has been correlated with the occurrence of HD symptoms. Further, the abnormal huntingtin protein appears to accumulate abnormally in neuronal nuclei. Thus, blocking the expression of huntingtin provides a useful mechanism to study HD pathogenesis and can also provide a potential treatment for HD.
- nucleic acid sequences of their study is homologous with both rhesus and human HD genes
- nucleic acid sequences of the present invention are known to be homologous with both rhesus ( Macaca mulatta ) and human ( Homo sapiens ) HD genes.
- one important benefit of the present invention is that the same nucleic acid sequences can be studied and characterized for toxicological and pharmacological properties and safety in the non-human primate Macaca mulatta and then, without alteration, can also be used for therapeutic benefit in Homo sapiens.
- RNA interference RNA interference
- a PCR strategy was used to clone and assemble 3437 bp of the 5′ portion of the rhesus HD gene.
- a series of PCR primers predicted to anneal to the rhesus HD cDNA were designed based on evolutionarily conserved sequences identified in an alignment of the human (NM — 002111) and pig (AB016793) cDNA sequences.
- primers were used to amplify partially overlapping portions of the rhesus HD gene from first strand cDNA prepared from rhesus brain and kidney tissues (BioChain Institute, Inc; C1534035 and C1534142 respectively) using high fidelity DNA polymerases.
- the recovered PCR products were cloned into pCR-Blunt-TOPO (Invitrogen) and sequenced using standard methods. Sequence alignments between multiple, independently derived clones were analyzed to ensure the elimination of potential PCR and sequencing errors. This sequence information was also used to design additional primers to clone gaps in the recovered HD cDNA sequence.
- a single composite clone containing 3437 bp of the rhesus HD cDNA was assembled using PCR and conventional cloning techniques.
- nucleic acid suppressor sequences for rhesus monkey huntingtin that correspond with portions of the human sequence (i.e., target genes were rhesus and human HD genes) were identified using online software (http://www.dharmacon.com/) and also obtained from Dharmacon® (Dharmacon Research, Inc., Boulder, Colo.). These nucleic acid sequences included those in the following Table 1:
- sequences in the preceding table can be considered target sequences as well as sequences included in the nucleic acid molecules of the present invention.
- SEQ ID NOS. 1-8 are 19 nucleotide base sequences.
- SEQ ID NO. 9-15 are the same sequences extended to 27 nucleotide base sequences. The sequence identified as SEQ ID NO. 7 was not extended into a 27 nucleotide base sequence because extending this sequence resulted in a mismatch between the rhesus monkey and human HD sequences.
- Control sequences also were chosen.
- the control sequences included a non-sense scrambled control (SEQ ID NO. 19; TAGCGACTAAACACATCAA) and a TNF ⁇ sequence (SEQ ID NO. 16; AATCCTCCTTCGTATTATA) both purchased from Dharmacon.
- rhesus monkey HD gene sequences were subcloned into pTracerTM-CMV2 (Invitrogen, Corp., Carlsbad, Calif.) to generate pTracer-rhuntingtin (pTRACER-rhHD).
- the recombinant plasmid also included a GFP-Zeocin reporter gene for transfection efficiency normalization.
- the CMV promoter directed constitutive expression of the target gene (rhesus monkey HD) while the EF1 promoter directed constitutive expression of the GFP-Zeocin reporter gene.
- the generated recombinant plasmids were used to facilitate screening of nucleic acid sequences by co-transfection into a eukaryotic cell line.
- HEK293 cell cultures at 60-70% confluency were co-transfected with the appropriate target plasmid (2 ⁇ g/well of a 6-well plate) and test nucleic acid sequences (100 nM) directed against rhesus monkey HD (SEQ ID NO: 1 through SEQ ID NO: 8), TNF ⁇ (as a control (SEQ ID NO. 16) or a non-sense scrambled control (SEQ ID NO. 19).
- SEQ ID NO: 1 through SEQ ID NO: 8 test nucleic acid sequences directed against rhesus monkey HD
- TNF ⁇ as a control (SEQ ID NO. 16)
- SEQ ID NO. 19 a non-sense scrambled control
- Forty-eight hours post-transfection total cellular RNA was harvested from the cells and used to make cDNA
- FIG. 2 shows the results of the rhesus monkey HD transfection studies related to each of the test nucleic acid sequence's ability to suppress rhesus monkey HD mRNA. As measured by realtime PCR, all non-control sequences effectively suppressed expression of the HD gene when compared to mock treated control cells (set at 100% expression). Because the nucleic acid sequences evaluated in the present experiment have complete sequence identity to portions of the human HD gene. sequence, it is reasonable to expect that they also suppress the expression of the human HD gene, thus suppressing production of human huntingtin protein.
- the cDNAs were used to analyze for rhesus HD and control gene expression using realtime PCR methods.
- FIG. 3 all sequences directed against rhesus HD mRNA suppressed rhesus HD gene expression at both doses when compared to controls.
- 4MBr5 cells were transfected as described above but with 100 nM, 10 nM, 1.0 nM, 0.2 nM or 0.05 nM of SEQ ID NO: 4 (19 nucleotide sequence); 100 nM, 10 nM, 1.0 nM, 0.2 nM or 0.05 nM of SEQ ID NO: 12 (corresponding 27 nucleotide sequence); 100 nM SEQ ID NO: 19 (scrambled) or 100 nM SEQ ID NO: 16 (off-target TNF ⁇ control). As shown in FIG.
- LLC-MK2 cells (a rhesus kidney cell line also obtained from ATCC) at 70-80% confluency were transfected with test nucleic acid sequences (SEQ ID NO: 4 and SEQ ID NO: 12) at one of two doses, 10 nM or 0.2 nM as well as controls (SEQ ID NO: 19 and SEQ ID NO: 16) at 100 nM.
- the cDNAs were used to analyze for rhesus HD and control gene expression using realtime PCR methods.
- FIG. 5 all sequences directed against rhesus HD mRNA suppressed rhesus HD gene expression at both doses when compared to controls.
- LLC-MK2 cells were transfected with 100 nM, 10 nM, 1 nM, 0.1 nM or 0.01 nM SEQ ID NO: 1 (19 nucleotide sequence); 10 nM, 1 nM, 0.1 nM or 0.01 nM SEQ ID NO: 9 (corresponding 27 nucleotide sequence); or control SEQ ID NOS: 19 or 16 (100 nM). As shown in FIG.
- a subset of the identified siNA sequences was tested for the chosen sequence's ability to suppress expression of the endogenous human HD gene.
- HeLa cells obtained from ATCC at 70-80% confluency were transfected with test nucleic acid sequences (SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 4; SEQ ID NO: 6; or SEQ ID NO: 7) or control (SEQ ID NO: 19) at 100 nM.
- test nucleic acid sequences SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 4; SEQ ID NO: 6; or SEQ ID NO: 7
- control SEQ ID NO: 19
- Protein was harvested 48 hours post-transfection and was analyzed using western blot analysis. In this analysis, 10 ⁇ g of total protein was loaded per well. Rhesus huntingtin protein expression was measured using the Chemicon® International (Temecula, Calif.) huntingtin antibody MAB2168 and ⁇ -actin was measured with abcam® (Cambridge, Mass.) antibody 20272-100. To quantify huntingtin protein expression the intensities of the bands for huntingtin and ⁇ -actin on the autoradiogram of the western blot were measured by densitometry. Huntingtin protein expression was normalized to ⁇ -actin expression. As can be seen in FIG.
- both SEQ ID NO: 1 and SEQ ID NO: 4 were effective to suppress exogenous huntingtin protein expression when compared to controls transfected with the pTRACER-rhHD plasmid and SEQ ID NO: 19 or the pTRACER-rhHD plasmid alone.
- LLC-MK2 cells were transfected with 100 nM of either SEQ ID NO: 1, SEQ ID NO: 4 or SEQ ID NO: 19.
- An additional control consisted of extracts from untransfected cells. Protein was harvested and analyzed 48 hours post-transfection with 10 ⁇ g of total protein loaded per western blot well. Again, rhesus huntingtin protein expression was measured using the Chemicon® International (Temecula, Calif.) huntingtin antibody MAB2168 and ⁇ -actin was measured with abcam® (Cambridge, Mass.) antibody 20272-100.
- both SEQ ID NO: 1 and SEQ ID NO: 4 suppress huntingtin protein expression.
- the level of rhesus huntingtin protein expression was normalized to ⁇ -actin expression.
- the intensities of the bands on the autoradiogram of the western blot were measured by densitometry.
- SEQ ID NO: 1 and SEQ ID NO: 4 both suppressed endogenous huntingtin protein expression when compared to cells transfected with control SEQ ID NO: 19 or to extract from untransfected cells.
- FIG. 12 shows SEQ ID NO: 4 reformatted and constructed as an anti-huntingtin shNA sequence (SEQ ID NO: 17; FIG. 12A ).
- FIG. 12 also shows a control shNA sequence (SEQ ID NO: 18; FIG. 12B ).
- the shNA sequences contain the siNA nucleic acid sequence (boxed sequence shown in black; in FIG. 12A , an originally effective nucleic acid sequence), a nine nucleotide loop (underlined), the reverse complement of the boxed nucleic acid sequence (italicized), and a Pol III terminator sequence (TTTTTT (bolded)).
- oligonucleotides can be used to assemble the shNAs.
- the 1 ⁇ 3 and 2/4 oligonucleotides for each shNA can be annealed.
- the A1 and B1 oligonucleotides include the boxed sequences.
- the A2 and B2 oligonucleotides include the underlined nine nucleotide loop, the reverse complement of oligonucleotides A1 and B1 respectively, the bolded Pol III terminator sequence (TTTTTT) and the first G of the EcoRI site depicted in these FIGS.
- the A3 and B3 oligonucleotides of FIGS. 12A and 12B respectively include the ApaI overhang region, the reverse complement of the boxed A1/B1 sequences, and the reverse complement of the underlined nine nucleotide loop sequence.
- the A4 and B4 oligonucleotides include the reverse complement of the italicized portion of A2 and B2 respectively and the reverse complement (AAAAAA) of the bolded Pol III terminator sequence. Finally, the A4 and B4 oligonucleotides contain the EcoRI overhang region. ApaI and EcoRI restriction enzyme-compatible ends are included in the shNA structures for directional subcloning into a murine U6 promoter-containing shuttle vector (pSilencer1.0-U6 ; Ambion, Inc., Austin, Tex.; FIG. 15 ).
- the full-length shNAs (SEQ ID NOS: 17 and 18) then can be cloned into a ApaI/EcoRI-digested pSilencer vector using a three-way ligation reaction.
- the U6 promoter (murine or human) is used for constitutive high level expression of the nucleic acid sequences.
- a human H1 promoter can also be used.
- a shuttle vector containing the human U6 promoter is psiSTRIKETM hmGFP from Promega Corporation (Madison, Wis.).
- a shuttle vector containing the human H1 promoter is pSilencer 3.0-H1 from Ambion, Inc, (Austin, Tex.).
- the loop structure of the shNA hairpin is 4 to 10 nucleotides in length.
- the arms of the hairpin structures are less than approximately 30 nucleotides in length.
- the arms of the hairpin structure are between 19 and 27 nucleotides in length.
- SEQ ID NO: 21 is a modified version of control SEQ ID NO: 18.
- SEQ ID NO. 20 SEQ ID NO. 21
- SEQ ID NO. 22 FIG. 13C ; modified SEQ ID NO: 17-EB4 (as will be recognized by one of ordinary skill in the art, SEQ ID NO: 22 includes SEQ ID NO: 17 with modified overhang regions for subcloning into a different vector)
- SEQ ID NO: 23 FIG. 13D ; modified SEQ ID NO: 17-mir23
- SEQ ID NO: 24 FIG.
- FIG. 13E shNA-modified SEQ ID NO: 12-EB4; and SEQ ID NO: 25 ( FIG. 13F ; shNA-modified SEQ ID NO: 12-mir23).
- FIG. 14 all test plasmids suppressed rhesus HD gene expression when compared to control plasmids.
- the BamHI fragment ( FIG. 15 ) containing the shNA expression cassette (murine U6 promoter, shNA sequence, and Pol III terminator sequence) from each of the pSilencer shuttle vectors (huntingtin and control) is recovered, blunted with T4 DNA polymerase, and subcloned into an AAV1/2 expression vector (deprAVETM; GeneDetect.com Ltd, Bradenton, Fla.). As shown in FIG.
- the U6 promoter (murine or human) can drive the expression of the shNA and the Woodchuck enhancer/chicken ⁇ -actin promoter can drive the expression of the enhanced green fluorescent protein (WPRE/CAG-eGFP).
- WPRE/CAG-eGFP enhanced green fluorescent protein
- These expression cassettes can be flanked by viral inverted terminal repeats (ITR).
- ITR viral inverted terminal repeats
- WPRE Woodchuck post-transcriptional regulatory element
- BGH bovine growth hormone
- the expression cassette additionally contains a polyadenylation signal, such as a synthetic minimal polyadenylation signal.
- the H1 promoter can be used.
- FIG. 17 depicts a different plasmid, the plasmid used to construct pAAV vectors used in the following experiments to generate AAV (pAAV-hrGFP, Stratagene, La. Jolla, Calif.).
- Six different plasmids were constructed; 3 with an H1 promoter and 3 with a U6 promoter (human H1 promoter from Ambion (Austin, Tex.) and human U6 promoter from Promega (Madison, Wis.)).
- U6-SEQ ID NO: 17 The following were subcloned into the depicted vector (1) U6-SEQ ID NO: 17; (2) U6-SEQ ID NO: 26 (SEQ ID NO: 26 is SEQ ID NO: 1 in an shRNA format; see FIG.
- SEQ ID NO: 27 is a scrambled SEQ ID NO: 1 shNA control; see FIG. 18B ).
- This PvuII fragment was then subcloned into the blunted MluI site of pAAV-hrGFP (Stratagene, La. Jolla, Calif.). Directionality was confirmed by restriction digest mapping and sequence analysis.
- pAAV plasmids were co-transfected into HEK293T cells along with pTRACER-rhHD ( FIG. 1 ).
- siRNAs SEQ ID NOS: 1 or 4
- SEQ ID NO: 19 the non-sense scrambled control
- pTRACER-rhHD was also transfected alone as a control.
- RNA was collected 48 hours post transfection and the suppression of rhesus HD gene expression (on the pTRACER plasmid) was measured by realtime PCR and normalized to the amount of GFP expressed from the pTRACER-rhHD plasmid. As can be seen in FIG.
- pAAV plasmids containing U6-SEQ ID NO: 17; U6-SEQ ID NO: 26; H1-SEQ ID NO: 17; and H1-SEQ ID NO: 26 were as effective at suppressing exogenous rhesus HD gene expression as previously tested SEQ ID NO: 1 and SEQ ID NO: 4.
- pAAV plasmids expressing scrambled control sequences did not suppress exogenous rhesus HD gene expression.
- AAV adeno-associated virus
- Five separate AAV viruses were generated. These viruses were engineered to express U6-SEQ ID NO: 26; U6-SEQ ID NO: 17; H1-SEQ ID NO: 26; U6-SEQ ID NO: 18 (shNA control) or H1-SEQ ID NO: 27 (shNA control). The ability of these viruses to suppress endogenous human HD gene expression in HeLa cells and HEK293T cells was examined.
- the cDNAs were analyzed for HD and GAPDH expression levels by realtime PCR methods. Endogenous HD expression was normalized to endogenous GAPDH expression. As shown in FIG. 20 , U6-SEQ ID NO: 26 and U6-SEQ ID NO: 17 were effective at suppressing endogenous human HD gene expression. P values were determined by comparison to the mock transduced data set. In this experiment, even though H1-SEQ ID NO: 26 did not significantly suppress endogenous human HD expression in vitro, its potential effectiveness in vivo should not be discounted especially in light of literature indicating a potential disconnect between in vitro and in vivo activity. See, for example, Wooddell et al., 334 Biochem. and Biophys. Res. Comm. 117-27 (2005).
- the siNA sequences and molecules of the present invention can be manipulated to enhance their uptake into the RISC complex.
- manipulating the 3 prime terminal nucleotide of the sense strand can be highly advantageous.
- Preferential entry of the guide, or antisense, strand into RISC can be achieved by introducing 3 prime mismatches in the sense strand while maintaining perfect base pairing (of the antisense strand and the intended mRNA target) at the 5 prime terminus of the antisense strand. This maximizes entry of the antisense strand into the RISC complex, while also reducing potential off-target inhibition by the sense strand.
- nucleic acid molecules and/or their carriers i.e. vectors
- Some of these methods include, without limitation, calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, lipofection, protoplast fusion, particle bombardment, microinjection, liposome fusion, biolistics and other suitable methods found in, for example, Sambrook, et al. (Molecular Cloning: A Laboratory Manual, 2nd, ed, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.
- viral vectors For mammalian gene therapy, viral vectors, and especially retroviral vectors, have become the most widely used method for inserting genes into mammalian, e.g., rhesus monkey or human cells.
- Other viral vectors can be derived from poxviruses, herpes simplex virus I, adenoviruses and adeno-associated viruses, and the like (see, for example, Boenisch et al., U.S. Pat. No. 5,350,674 and Wilson et al., U.S. Pat. No. 5,585,362 which are hereby incorporated by reference).
- Embodiments of the present invention also can be delivered through the use of liposomes, polyethyleneimine, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres.
- Nucleic acid molecules also can be directly delivered to cells or tissues with or without the aforementioned vehicles.
- the nucleic acid molecules/vehicle combinations can be locally delivered by catheter and drug pump systems, delivered by direct local injection or through the use of polymers and/or drug-eluting stents.
- the nucleic acid sequences, molecules, expression cassettes and vectors of the present invention can be used to suppress HD gene expression and resulting huntingtin formation.
- the nucleic acid sequences, molecules, expression cassettes and vectors of the present invention also can be used in the study of HD pathogenesis.
- the nucleic acid sequences, molecules, expression cassettes and vectors of the present invention also may be administered to prevent or treat the symptoms of HD.
- the amount of these agents administered as well as the timing of their delivery will vary depending on various factors including, for example and without limitation, the composition chosen, the weight, physical condition, and age of the patient, and whether prevention or treatment is desired as well as other factors known to skilled practitioners.
- Administration of the therapeutic agents can be continuous or intermittent.
- the administration of the agents of the invention can be essentially continuous over a preselected period of time or can be in a series of spaced doses. Further, both local and systemic administration can be appropriate for use within the present invention. Such factors can be determined by the researcher or treating physician.
- a pre-clinical study of the safety of suppressing huntingtin protein expression in the normal adult rhesus monkey brain was conducted.
- a 6 year old female rhesus monkey weighing approximately 3.9 kg was anesthetized and bilaterally infused with an anti-HD shRNA/GFP-containing recombinant adeno-associated virus (AAV) (AAV-U6-SEQ ID NO: 17 (serotype AAV1; 2.07 ⁇ 10 12 vg/ml; lot #J0531)) by stereotactic injection.
- AAV anti-HD shRNA/GFP-containing recombinant adeno-associated virus
- Injections Halton syringe (100 ⁇ l) with 27 Ga needle (compression fitting)) were performed at 2 putamen sites (50 ⁇ l/site) using a single needle tract and 1 caudate site (50 ⁇ l) at a rate of 1 ⁇ l/min. Following this injection, the needle was left in place for at least 20 minutes and then withdrawn at a rate of 1 mm/min.
- the animal was deeply anesthetized with pentobarbital (1.5 ml intramuscular; 2 ml, intravenous) and transcardially perfused with heparinized ice-cold saline (4-6 L). Following perfusion and removal, the brain was placed into a container of ice-cold saline.
- the right hemisphere of the brain was sectioned into 14-4 mm thick coronal sections and numbered 1-14 (rostral to caudal).
- a 14G biopsy needle was then used to collected tissue punches from various brain regions.
- a total of 103 tissue punches was collected from the right hemisphere. Each tissue punch contained about 6 mg of tissue and was snap frozen in liquid nitrogen and stored at ⁇ 80° C. until RNA was isolated.
- the left hemisphere of the brain was sectioned into 4 blocks (rostral to caudal).
- Block 1 was 10 mm; blocks 2 and 3 were 16 mm; and block 4 was 20 mm.
- Each block was embedded in OCT, snap frozen in isopentane and stored at ⁇ 80° C.
- Ten micron sections were then collected and placed onto laser microdissection (LMD) compatible slides. Tissue on the slides was fixed in ethanol (30 seconds in 75% ethanol; 30 seconds in 95% ethanol; and 30 seconds in 100% ethanol) with an air dry between steps. Slides were then screened to identify the ones containing brain regions of interest (i.e. caudate and putamen) and data on viral spread was obtained by following the expression of the marker gene (GFP).
- GFP positive regions were collected by LMD from the caudate and putamen.
- a pre-clinical study of the safety of suppressing huntingtin protein expression in the normal adult rhesus monkey brain is conducted over a 12-month period.
- six rhesus macaques ( Macaca mulatta ) are trained to perform the tasks of a commercially available computerized behavioral test battery (Monkey CANTAB, Model 80650, Lafayette Instruments, Lafayette, Ind.) that is based upon human neuropsychological tests (CANTAB, CeNeS, Cambridge, UK).
- the performance of these six monkeys on the test battery is compared to previously published performance norms for rhesus monkeys to verify that the monkey's cognitive abilities are within normal limits. See, for example, Weed et al., Brain Research: Cognitive Brain Research, 1999, Oct. 25; 8(3) 185-201.
- the monkeys are randomly assigned to one of two experimental groups: the first group of three monkeys receives intracranial injections of an adeno-associated virus (AAV) vector comprising an expression cassette containing an RNA polymerase III promoter driving expression of a short hairpin RNA transcript encoding for the shNA of SEQ ID NO: 17.
- a second expression cassette in the same vector encodes for a green fluorescent protein reporter gene.
- the second group of three monkeys receives intracranial injections of an adeno-associated virus vector comprising an expression cassette containing the same RNA polymerase III promoter driving expression of a control shNA sequence (SEQ ID NO:18).
- a second expression cassette in this vector encodes for a green fluorescent protein reporter gene.
- the AAV vector is administered to the caudate nucleus and putamen of each hemisphere of each monkey's brain.
- the amount of AAV vector administered in each intracranial injection, and the surgical method and procedures for making these injections, are well-known to those skilled in the art.
- the monkeys are repeatedly tested on a periodic basis using the Monkey CANTAB computerized testing battery for the remainder of the twelve-month study period.
- the cognitive and behavioral performance of each monkey over time is compared to its own pre-operative performance. No statistically significant decline in cognitive or behavioral performance measures is obtained for either the monkeys treated with the control shNA vector, or the monkeys treated with the anti-rhesus-HD shNA vector. This indicates that there are no significant cognitive or behavioral consequences of suppressing the expression of huntingtin protein in the caudate and putamen of the adult primate brain.
- Periodic neurological examinations of each monkey by skilled and qualified veterinarians unaware of the experimental group membership of each monkey also shows no neurological deficits in the monkeys.
- the monkeys are humanely terminated, and the brain of each monkey is removed and examined for abnormalities by trained pathologists. In addition, it is studied by fluorescence microscopy, immunohistochemistry, and molecular and biochemical assays.
- the regions of the brain in which the AAV vector effectively delivered the shNA are identified by fluorescence microscopy. This reveals expression of the green fluorescent protein reporter gene in substantial regions of the caudate nucleus and putamen in each hemisphere of each monkey's brain.
- Immunohistochemical staining for huntingtin protein shows reduced levels of huntingtin protein in the caudate and putamen of the monkeys who received the anti-rhesus-HD shNA vector, compared to the monkeys who received the control shNA vector, indicating suppression of huntingtin protein expression by the shNA of the invention.
- homogenized brain tissue samples from the caudate and putamen of each monkey's brain are assayed for levels of rhesus HD mRNA measured by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) assay, and for levels of rhesus huntingtin protein measured by Western blotting, using methods well-known to those skilled in the art.
- qRT-PCR quantitative reverse transcriptase polymerase chain reaction
- the same shNA expression cassette that is used in the pre-clinical safety tests in rhesus monkeys is engineered into an AAV vector using methods well-known to those skilled in the art.
- This AAV vector comprises an expression cassette containing an RNA polymerase III promoter driving expression of a short hairpin RNA transcript encoding for the shNA of SEQ ID NO: 17.
- the AAV vector optionally does not contain a second expression cassette encoding for a green fluorescent protein reporter gene, because this expression cassette is not needed for the treatment of HD in patients.
- an AAV vector comprising an expression cassette containing SEQ ID NO: 17 is effective at suppressing the expression of the Homo sapiens HD gene and huntingtin protein, as well as the Macaca mulatta HD gene and huntingtin protein.
- the AAV vector can be administered to the human patient's brain according to the systems and methods disclosed in U.S. Patent Application Numbers 20040162255 and 20040220132. These trials establish that suppression of huntingtin protein in the caudate and putamen of human patients afflicted with HD using the nucleic acid molecules, expression cassettes, or vectors of the present invention is effective at arresting and partially reversing the cognitive and motor deficits in patients treated after onset of these symptoms of the disease.
- 3*10 11 viral particles comprising AAV vectors including shNAs of SEQ ID. NO: 26 or SEQ. ID. NO: 17 or a control shNA (SEQ. ID. NO: 18) under regulation of the human U6 promoter upstream of GFP sequence under control of CMV promoter were injected into Rhesus moneys as follows:
- Huntington (HD) mRNA was quantified by qPCR using total RNA isolated from tissue punches and laser microdissected sections (LMD). Huntingtin protein was quantified by western blot analysis using total protein isolated from tissue punches.
- the amount of HD mRNA was decreased by about 65% to 70% in the GFP-expressing areas compared to the areas not expressing GFP, as measured by qPCR of RNA isolated from LMD sections.
- the animals were injected according to the protocol of the previous example. Histopathological analyses were conducted by analyzing GFP fluorescence, hematoxylin-eosin (H&E) staining, huntingtin immunofluorescent staining, calnexin immunofluorescent staining and protein disulfide isomerase (PDI) immuofluorescent staining.
- H&E hematoxylin-eosin
- PDI protein disulfide isomerase
- the animals were injected according to the protocol of Working Example 1. Spontaneous activity and fine motor activity were also measured by EthnoVision and mMAP equipment, respectively.
- EthnoVision is a video tracking system that can be used to measure distance traveled, body movement speed and vertical activity. Associated computer software is able to quantify each of these parameters.
- mMAP monkey Movement Analysis Panel
- the present invention is not limited to the particular embodiments, materials, and examples described herein, as these can vary.
- the nucleic acid molecules of the present invention can be created in a variety of formats and lengths. Indeed, those skilled in the art will recognize that the most important attribute of the nucleic acid molecules of the present invention is their ability to enter the RISC complex and also complementarily bind to the mRNA sequences of interest to induce an RNA interference effect, resulting in reduction of the mRNA stability and/or the translation rate of these sequences.
- the phrase “complementarily bind” as used herein, refers to the abilities of the nucleic acid molecules to form hydrogen bond(s) with mRNA sequences by either traditional Watson-Crick pairing or other non-traditional types.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychology (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
- This application is a continuation-in-part of application Ser. No. 11/429,491 entitled “Methods and sequences to suppress primate huntington gene expression” by William F. Kaemmerer and Michael D. Kaytor, filed on May 4, 2006.
- The present invention relates to inhibitory nucleic acid molecules that suppress the expression of the Huntington's disease gene in primates, including rhesus monkeys (Macaca mulatta) and humans (Homo sapiens), and methods of use thereof.
- Huntington's disease (“HD”) is a neurodegenerative brain disorder with a juvenile or adult onset. It slowly destroys an affected individual's ability to walk, think, talk and reason. Symptoms include changes in cognitive ability, such as impaired short-term memory and a decreased ability to concentrate; changes in mood, such as the development of mood swings, depression and irritability; and changes in coordination and physical movement such as clumsiness, involuntary movements and twitching. These symptoms gradually worsen until HD patients die, approximately 15-20 years after the onset of the disease.
- While the biochemical cause of HD is not yet fully understood, it is now known that HD is inherited as an autosomal dominant trait. This inheritance feature means that every individual who inherits a mutated (expanded) HD gene from either parent will develop the disease.
- One breakthrough in research regarding HD has been the identification of the mutated gene that causes HD. Based on this breakthrough, researchers and physicians now can predict which individuals will develop HD. Specifically, researchers and physicians can predict which individuals will develop HD by counting the number of “CAG repeats” that exist within a given individual's HD gene. If a person has 35 or fewer CAG repeats in both of their HD genes, that person will not develop HD. If a person has more than 35 CAG repeats in either of their HD genes, that person will develop the disease. The more CAG repeats a person has over 35, the earlier the person will develop the symptoms of HD.
- The HD gene encodes for a protein called “huntingtin” (also known as “htt”). The exact function of huntingtin is not known. The expression of a mutant, expanded huntingtin protein is known to be the cause of HD, however. Some of the evidence that has led scientists to this conclusion includes mouse studies showing that the introduction of an expanded HD transgene in the mouse leads to the pathological and behavioral features of HD and its removal can resolve these effects. Thus, suppressing the production of huntingtin in brain cells may prevent or alleviate the symptoms or occurrence of HD.
- Recent developments in genetic technologies have made the selective suppression of certain proteins, such as huntingtin, possible. Some background in the art is required to understand the potential impact of these technologies. Generally, for a protein to exert an effect, the cell that will use the protein must create it. To create a protein the cell first makes a copy of the protein's gene sequence in the nucleus of the cell. This copy of the gene sequence that encodes for the protein (called messenger RNA (“mRNA”)) leaves the nucleus and is trafficked to a region of the cell containing ribosomes. Ribosomes read the sequence of the mRNA and create the protein for which it encodes. This process of new protein synthesis is known as translation. A variety of factors affect the rate and efficiency of protein translation. Among the most significant of these factors is the intrinsic stability of the mRNA itself. If the mRNA is degraded quickly within the cell (such as before it reaches a ribosome), it is unable to serve as a template for new protein translation, thus reducing the cell's ability to create the protein for which it encoded.
- Based on the foregoing, the technology of RNA interference (“RNAi”) has emerged. RNA interference is, in fact, a naturally-occurring mechanism for suppressing gene expression and subsequent protein translation. RNA interference suppresses protein translation by either degrading the mRNA before it can be translated or by binding the mRNA and directly preventing its translation. This naturally-occurring mechanism of RNA interference can also be artificially induced to occur in cells. For example, RNA interference can be achieved by introducing into cells short, double-stranded nucleic acid oligonucleotides corresponding to the mRNA for the gene to be suppressed, or by introducing into cells a sequence of DNA that encodes for a short, hairpin transcript of nucleic acids that folds back upon itself and forms a short, double-stranded nucleic acid oligonucleotide following further processing in the cell. This technology provides a means to suppress the expression of huntingtin in cells. The suppression of huntingtin in cells can be useful in the study of HD pathogenesis. Suppressing huntingtin in a patient also could prevent or alleviate the symptoms of HD.
- The present invention describes methods, nucleic acid sequences and molecules, expression cassettes, and vectors for using RNA interference (“RNAi”) to suppress expression of the HD gene. Suppressing expression of the HD gene can reduce levels of huntingtin within cells. This suppression and reduction can be useful in the study of HD pathogenesis. This suppression and reduction also can be useful in the prevention and treatment of the symptoms of HD. Specifically, RNAi is mediated by double stranded RNA (“dsRNA”), short hairpin RNA (“shRNA”) or other nucleic acid molecules with similar characteristics. These nucleic acid molecules are processed or cut into smaller pieces by cellular enzymes including Dicer and Drosha. The smaller fragments of the nucleic acid molecules can then be taken up by a protein complex called the RNA-induced silencing complex (“RISC complex”) that mediates degradation of mRNAs. The RISC complex will degrade mRNA that complementarily base pairs with the nucleic acid molecules it has taken up. In this manner, the mRNA is specifically destroyed, thus preventing the protein for which the mRNA encoded from being made.
- The understanding of the mechanism of RNAi now allows geneticists to create nucleic acid molecules with sequences that are homologous to known gene sequences in order to suppress the expression or formation of certain proteins within a cell. In this invention, nucleic acid sequences and molecules that are homologous to primate HD mRNA sequences are introduced into cells to suppress expression of huntingtin protein. These nucleic acid sequences and molecules specifically suppress the expression of mRNA sequences that encode for primate huntingtin protein, including rhesus monkey and human huntingtin. Suppressing expression of this protein can be useful in the study of HD pathogenesis. This suppression also could be useful in the prevention and/or treatment of HD.
- In one embodiment of the present invention, the invention includes a nucleic acid molecule comprising a first strand and a second strand wherein the first strand comprises a nucleotide sequence and wherein the second strand comprises the reverse complement of said first strand and wherein the nucleic acid molecule suppresses the expression of both Macaca mulatta and Homo sapiens mRNA sequences that encode for huntingtin.
- In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 1 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 2 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 3 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 4 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 5 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 6 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 7 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 8 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 9 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 10 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 11 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 12 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 13 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 14 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 19 contiguous nucleotides encoded by SEQ ID NO: 15 and wherein the second strand is complementary to at least 15 contiguous nucleotides of the first strand.
- In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 27 contiguous nucleotides encoded by SEQ ID NO: 9 and wherein the second strand is complementary to at least 23 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 27 contiguous nucleotides encoded by SEQ ID NO: 10 and wherein the second strand is complementary to at least 23 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 27 contiguous nucleotides encoded by SEQ ID NO: 11 and wherein the second strand is complementary to at least 23 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 27 contiguous nucleotides encoded by SEQ ID NO: 12 and wherein the second strand is complementary to at least 23 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 27 contiguous nucleotides encoded by SEQ ID NO: 13 and wherein the second strand is complementary to at least 23 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 27 contiguous nucleotides encoded by SEQ ID NO: 14 and wherein the second strand is complementary to at least 23 contiguous nucleotides of the first strand. In another embodiment of the present invention, the invention includes an isolated nucleic acid duplex comprising a first strand of nucleic acid and a second strand of nucleic acid, wherein the first strand comprises at least 27 contiguous nucleotides encoded by SEQ ID NO: 15 and wherein the second strand is complementary to at least 23 contiguous nucleotides of the first strand.
- In one embodiment of the present invention, the nucleic acid duplex is between 19 and 30 base pairs in length.
- In another embodiment of the present invention, the first and/or second strand of the nucleic acid duplex comprises an overhang region. In another embodiment of the present invention, the first and/or second strand of the nucleic acid duplex comprises a 3′ overhang region, a 5′ overhang region, or both 3′ and 5′ overhang regions. In another embodiment of the present invention, the first and/or second strand of the nucleic acid duplex comprises an overhang region that is from approximately 1 to approximately 10 nucleotides in length.
- In another embodiment of the present invention, the first and second strand of the nucleic acid duplex are operably linked by means of a nucleic acid loop strand that forms a hairpin structure comprising a duplex structure and a loop structure. In another embodiment of the present invention, the first and second strand of the nucleic acid duplex are operably linked by means of a nucleic acid loop that contains from 4 to 10 nucleotides.
- In another embodiment of the present invention, the invention includes an expression cassette. In one embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 1. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 2. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 3. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 4. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 5. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 6. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 7. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 8. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 9. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 10. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 11. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 12. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 13. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 14. In another embodiment, the expression cassette comprises a nucleic acid sequence encoding SEQ ID NO: 15.
- In one embodiment of the present invention, the expression cassette also comprises a promoter. In another embodiment of the present invention, the expression cassette comprises a regulatable promoter. In another embodiment of the present invention, the expression cassette comprises a constitutive promoter. In another embodiment of the present invention, the expression cassette comprises a promoter that is a cytomegalovirus (“CMV”) promoter. In another embodiment of the present invention, the expression cassette comprises a promoter that is a Rous sarcoma virus (“RSV”) promoter. In another embodiment of the present invention, the expression cassette comprises a promoter utilized by RNA polymerase II. In another embodiment of the present invention, the expression cassette comprises a promoter utilized by RNA polymerase III.
- In one embodiment of the present invention, the expression cassette comprises a polyadenylation signal. In another embodiment of the present invention, the expression cassette comprises a polyadenylation signal that is a synthetic minimal polyadenylation signal. In another embodiment of the present invention, the expression cassette comprises a marker gene.
- In one embodiment of the present invention, the invention includes a vector comprising one or more of the expression cassettes previously described. In another embodiment of the present invention, the vector comprises a first and a second expression cassette.
- In one embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 1 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 1. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 2 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 2. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 3 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 3. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 4 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 4. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 5 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 5. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 6 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 6. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 7 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 7. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 8 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 8. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 9 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 9. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 10 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 10. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 11 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 11. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 12 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 12. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 13 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 13. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 14 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 14. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 15 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 15 contiguous nucleotides of SEQ ID. NO. 15.
- In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 9 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 23 contiguous nucleotides of SEQ ID. NO. 9. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 10 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 23 contiguous nucleotides of SEQ ID. NO. 10. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 11 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 23 contiguous nucleotides of SEQ ID. NO. 11. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 12 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 23 contiguous nucleotides of SEQ ID. NO. 12. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 13 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 23 contiguous nucleotides of SEQ ID. NO. 13. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 14 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 23 contiguous nucleotides of SEQ ID. NO. 14. In another embodiment, the first expression cassette of the vector encodes a nucleotide sequence encoding for SEQ ID NO. 15 and the second expression cassette of the vector encodes for a nucleotide sequence that is complementary to at least 23 contiguous nucleotides of SEQ ID. NO. 15.
- In one embodiment of the present invention, the vector is a viral vector. In another embodiment of the present invention, the vector is an adenoviral virus vector. In another embodiment of the present invention, the vector is a lentiviral virus vector. In another embodiment of the present invention, the vector is an adeno-associated viral (AAV) virus vector. In another embodiment of the present invention, the vector is a poliovirus vector. In another embodiment of the present invention, the vector is a herpes simplex virus vector. In another embodiment of the present invention, the vector is a feline immunodeficiency virus vector. In another embodiment of the present invention, the vector is a murine Maloney-based viral vector.
- In another embodiment of the present invention, the vector comprises a promoter. In another embodiment of the present invention, the vector comprises an inducible promoter.
- In one embodiment of the present invention, the invention includes a cell comprising a previously-described expression cassette. In another embodiment of the present invention, the cell is a mammalian cell. Another embodiment of the present invention includes a non-human mammal comprising a previously-described expression cassette.
- The embodiments of the present invention also include methods. One method of the present invention includes a method of suppressing the accumulation of huntingtin in a cell comprising introducing a previously-described nucleic acid duplex into the cell in an amount sufficient to suppress accumulation of huntingtin in the cell. In another method of the present invention, accumulation of huntingtin is suppressed by at least 10%.
- Another method of the present invention includes a method of preventing cytotoxic effects of mutant huntingtin in a cell comprising introducing a previously-described nucleic acid duplex into the cell in an amount sufficient to suppress accumulation of the mutant huntingtin so that the nucleic acid duplex prevents cytotoxic effects of mutant huntingtin in the cell.
- Another method of the present invention includes a method of inhibiting expression of a huntingtin gene in a cell comprising introducing a previously-described nucleic acid duplex into the cell in an amount sufficient to inhibit expression of huntingtin so that the nucleic acid duplex inhibits expression of huntingtin.
- Another method of the present invention includes a method of inhibiting expression of huntingtin in Macaca mulatta and Homo sapiens comprising providing a Macaca mulatta or Homo sapiens containing a neuronal cell that contains and expresses the huntingtin gene and is susceptible to nucleic acid interference and contacting the Macaca mulatta or Homo sapiens with a previously-described nucleic acid duplex thereby inhibiting expression of the huntingtin gene. In another method of the present invention, expression of huntingtin is inhibited by at least 10%.
- Another method of the present invention includes a method of preventing cytotoxic effects of Huntington's disease (“HD”) in a Macaca mulatta or Homo sapiens comprising introducing a previously-described vector into a cell in an amount sufficient to suppress accumulation of a protein associated with HD, so that the resulting nucleic acid duplex prevents the cytotoxic effects of HD.
- Another method of the present invention includes a method of inhibiting expression of the huntingtin gene in a Macaca mulatta or Homo sapiens comprising introducing a previously-described vector into a cell in an amount sufficient to inhibit expression of the huntingtin gene so that the resulting nucleic acid duplex inhibits expression of the huntingtin protein.
- Another method of the present invention includes a method of inhibiting expression of huntingtin in a Macaca mulatta or Homo sapiens comprising providing a Macaca mulatta or Homo sapiens containing a neuronal cell, wherein the neuronal cell contains and expresses the huntingtin gene and is susceptible to nucleic acid interference, and contacting the Macaca mulatta or Homo sapiens with a previously-described vector, thereby inhibiting expression of the huntingtin gene.
- Additional method of the present invention includes a method of preventing cytotoxic effects of Huntington's disease (“HD”) in a Macaca mulatta or Homo sapiens comprising introducing the isolated nucleic acid duplex comprising SEQ ID. NO: 1 or SEQ. ID. NO: 4 into a cell in an amount sufficient to suppress accumulation of a protein associated with HD, and wherein the nucleic acid duplex prevents cytotoxic effects of HD.
- Additional method of the present invention includes a method of inhibiting expression of huntingtin in a Macaca mulatta or Homo sapiens comprising introducing the isolated nucleic acid duplex comprising SEQ ID. NO: 1 or SEQ. ID. NO: 4 into a cell in an amount sufficient to inhibit expression of huntingtin wherein said nucleic acid duplex inhibits expression of the protein associated with HD.
- In one embodiment of the present invention, the nucleic acid duplexes or vectors are administered to the intrathecal space of the spinal cord. In another embodiment of the present invention, the nucleic acid duplexes or vectors are administered to the cerebrospinal fluid in one or more of the cerebral ventricles of the brain. In another embodiment of the present invention, the nucleic acid duplexes or vectors are administered directly into the brain tissue of the cerebral cortex. In another embodiment of the methods of the present invention, the nucleic acid duplexes or vectors are administered locally to the basal ganglia. In another embodiment of the present invention, the nucleic acid duplexes or vectors are administered specifically to the caudate nucleus and the putamen.
-
FIG. 1 shows a target plasmid for nucleic acid sequence characterization in HEK293 cells. -
FIG. 2 shows rhesus monkey. HD mRNA suppression by siNA sequences in vitro in HEK293 cells. -
FIG. 3 shows suppression of the endogenous rhesus HD gene at two different siNA doses in 4MBR5 cells. -
FIG. 4 shows suppression of the endogenous rhesus HD gene at five different siNA doses using both 19 and 27 nucleotide length siNAs in 4MBR5 cells. -
FIGS. 5 and 6 show suppression of the endogenous rhesus HD gene using both 19 and 27 nucleotide length siNAs in LLC-MK2 cells. -
FIG. 7 also shows suppression of the endogenous rhesus HD gene using different doses of both 19 and 27 nucleotide length siNAs in LLC-MK2 cells. -
FIGS. 8A-8D show suppression of the endogenous human HD gene at 4 different siNA doses in HeLa cells. -
FIG. 9 shows suppression of exogenous rhesus huntingtin protein expression in LLC-MK2 cells. -
FIGS. 10 and 11 show suppression of endogenous rhesus huntingtin protein expression in LLC-MK2 cells. -
FIG. 12 depicts a structure and construction of anti-HD (FIG. 12A ) and control (FIG. 12B ) shNA sequences (antisense strands disclosed in SEQ. ID. NOS. 28 and 29, respectively in order of appearance). -
FIGS. 13A-F show additional shNA sequences used in embodiments according to the present invention (antisense strands disclosed in SEQ. ID. NOS. 30-35, respectively in order of appearance). -
FIG. 14 shows suppression of the endogenous rhesus HD gene in LLC-MK2 cells transfected with a plasmid expressing 19 or 27 nucleotide length shNAs with EB4 or mir23 loop structures. -
FIG. 15 shows a schematic description of a pSilencer 1.0-U6 plasmid that can be used in the preparation of anti-HD and control shNA sequences. -
FIG. 16 shows an exemplary format of AAV viral constructs. -
FIG. 17 shows a plasmid used to construct pAAV vectors and to generate AAV in accordance with the present invention. -
FIGS. 18A-B show additional shNA sequences used in embodiments according to the present invention (antisense strands disclosed in SEQ. ID. NO. 36 and 37, respectively, in order of appearance). -
FIG. 19 shows suppression of exogenous rhesus HD by pAAV plasmids. -
FIG. 20 shows suppression of endogenous human HD in HeLa cells and HEK293T cells by recombinant adeno-associated virus (AAV) expressing anti-HD shNA. -
FIGS. 21 and 22 show in vivo suppression of rhesus HD gene expression by recombinant adeno-associated virus (AAV) expressing anti-HD shNA. - The term “SEQ ID NO: X” (where X is any number from 1 to 15) refers to, in one embodiment, each number's sequence as defined in Table 1 (identified sequence). SEQ ID NO: X must also be read to encompass sequences that would hybridize with the complementary strand of a sequence set forth in SEQ ID NOS: 1-15 and reduce the particular SEQ ID NO:'s target mRNA in a cell type selected from, without limitation, HEK293 cells, 4MBR5 cells, LLC-MK2 cells, HeLA cells or any other Macaca mulatta or Homo sapien cell type. Under this definition, claimed sequences can include at least 99% sequence homology with the identified sequence; at least 98% sequence homology with the identified sequence; at least 95% sequence homology with the identified sequence; at least 90% sequence homology with the identified sequence; or at least 85% sequence homology with the identified sequence.
- The terms “nucleic acid” or “nucleic acid molecules” refer to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, composed of monomers (nucleotides) containing a sugar, phosphate and a base that is either a purine or pyrimidine. Unless specifically limited, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also encompasses conservatively modified variants thereof. The nucleic acid molecules of the present invention can include any type of nucleic acid molecule capable of mediating RNA interference, such as, without limitation, short interfering nucleic acid (siNA), short hairpin nucleic acid (shNA), short interfering RNA (siRNA), short hairpin RNA (shRNA), micro-RNA (miRNA), and double-stranded RNA (dsRNA). The nucleic acid molecules of the present invention also include similar DNA sequences. Further, the nucleic acid and nucleic acid molecules of the present invention can contain unmodified or modified nucleotides. Modified nucleotides refer to nucleotides which contain a modification in the chemical structure of a nucleotide base, sugar and/or phosphate. Such modifications can be made to improve the stability and/or efficacy of nucleic acid molecules and are described in patents and publications such as U.S. Pat. No. (“USPN”) 6,617,438, U.S. Pat. No. 5,334,711; U.S. Pat. No. 5,716,824; U.S. Pat. No. 5,627,053; U.S. Patent Application No. 60/082,404, International Patent Cooperation Treaty Publication Number (“PCTPN”) WO 98/13526; PCTPN WO 92/07065; PCTPN WO 03/070897; PCTPN WO 97/26270; PCTPN WO 93/15187; Beigelman et al., 1995, J. Biol. Chem., 270, 25702; Usman and Cedergren, 1992, TIBS. 17, 34; Usman et al., 1994, Nucleic Acids Symp. Ser. 31, 163; Burgin et al., 1996, Biochemistry, 35, 14090; Perrault et al. Nature, 1990, 344, 565-568; Pieken et al. Science, 1991, 253, 314-317; Usman and Cedergren, Trends in Biochem. Sci., 1992, 17, 334-339; Karpeisky et al., 1998, Tetrahedron Lett, 39, 1131; Earnshaw and Gait, 1998, Biopolymers (Nucleic Acid Sciences), 48, 39-55; Verma and Eckstein, 1998, Annu. Rev. Biochem., 67, 99-134; Burlina et al., 1997, Bioorg. Med. Chem., 5, 1999-2010; Limbach et al., 1994, Nucleic Acids Res. 22, 2183; and Burgin et al., 1996, Biochemistry, 35, 14090. Such patents and publications describe general methods and strategies to modify nucleic acid molecules and are incorporated by reference herein.
- The phrase “expression cassette” as used herein means a nucleic acid sequence capable of directing expression of a particular nucleotide sequence in an appropriate host cell, with additional sequences that facilitate appropriate transcription of the nucleic acid sequence of interest. In addition to the nucleotide sequence of interest, the expression cassette can include a promoter operably linked to the nucleotide sequence of interest that also can be operably linked to termination signals. The expression cassette also can include expression enhancers. The expression cassette including the nucleotide sequence of interest can be chimeric. The expression cassette also can be one that is naturally occurring but has been obtained in a recombinant form useful for heterologous expression. The expression of the nucleotide sequence in the expression cassette can be under the control of a constitutive promoter or of a regulatable promoter that initiates transcription only when the host cell is exposed to some particular stimulus. In the case of a multicellular organism, the promoter also can be specific to a particular tissue or organ or stage of development.
- The term “promoter” refers to a nucleotide sequence, usually upstream (5 prime) of the nucleotide sequence of interest, which directs and/or controls expression of the nucleotide sequence of interest by providing for recognition by RNA polymerase and other factors required for proper transcription. As used herein, the term “promoter” includes (but is not limited to) a minimal promoter that is a short DNA sequence comprised of a TATA-box and other sequences that serve to specify the site of transcription initiation, to which regulatory elements are added for control of expression. The term “promoter” also refers to a nucleotide sequence that includes a minimal promoter plus regulatory elements that is capable of controlling the expression of a coding sequence or functional RNA. This type of promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. The term “enhancer” refers to a DNA sequence that can stimulate promoter activity and can be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue specificity of a promoter. Enhancers are capable of operating in both orientations (normal or flipped), and are capable of functioning even when moved either upstream or downstream of the promoter. Both enhancers and other upstream promoter elements bind sequence-specific DNA-binding proteins that mediate their effects. Promoters can be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even be comprised of synthetic DNA segments. A promoter also can contain DNA sequences that are involved in the binding of protein factors that control the effectiveness of transcription initiation in response to physiological or developmental conditions. Specific promoters used in accordance with the present invention can include, for example and without limitation pol II promoters (including, without limitation cytomegalovirus (“CMV”) promoters, chicken β-actin (“CBA”) promoters, Rous sarcoma virus (“RSV”) promoters and neuron-specific enolase (“NSE”) promoters). Furthermore, specific promoters used in accordance with the present invention can include, for example and without limitation, pol III promoters (including, without limitation, human H1 and human or murine U6 promoters, as well as H1 and U6 promoters engineered to be expressed in a regulated way such as described in United States Patent Application Number 2005/0064489).
- The term “vector” is defined to include any virus, as well as any plasmid, cosmid, phage, binary vector or segment of nucleic acid (DNA or RNA) in double or single stranded linear or circular form that may or may not be self transmissible or mobilizable, and that can transform eukaryotic host cells either by integration into the cellular genome or by existing extrachromosomally (e.g., autonomous replicating plasmid with an origin of replication).
- The gene involved in Huntington's disease (“HD”) (IT15) is located on
chromosome 4 at the end of the short arm. This gene encodes for the protein huntingtin (also known as “htt”). The mutation in the HD gene responsible for HD is an unstable expanded CAG trinucleotide repeat within the coding region of the gene. This mutation results in a huntingtin protein with an expanded glutamine sequence. While the normal and abnormal functions of huntingtin are not known, the presence of the mutated form of huntingtin has been correlated with the occurrence of HD symptoms. Further, the abnormal huntingtin protein appears to accumulate abnormally in neuronal nuclei. Thus, blocking the expression of huntingtin provides a useful mechanism to study HD pathogenesis and can also provide a potential treatment for HD. A proof-of-principle that suppressing the expression of mutant huntingtin protein can be therapeutic for HD has been shown in mice by Harper et al. who showed that suppression of a mutant HD transgene in mice by use of RNA interference resulted in improvements in the disease phenotype of the transgenic mice. Proceedings of the National Academy of Sciences, 2005, 102(16) 5820-5825. It should be noted, however, that the present invention differs from this prior art in that the shNA sequence used and disclosed by Harper et al. is different from any and all of the nucleic acid sequences of the present invention. Furthermore, Harper et al. does not indicate whether the nucleic acid sequence of their study is homologous with both rhesus and human HD genes, whereas the nucleic acid sequences of the present invention are known to be homologous with both rhesus (Macaca mulatta) and human (Homo sapiens) HD genes. Thus, one important benefit of the present invention is that the same nucleic acid sequences can be studied and characterized for toxicological and pharmacological properties and safety in the non-human primate Macaca mulatta and then, without alteration, can also be used for therapeutic benefit in Homo sapiens. - In order to use RNA interference (“RNAi”) to suppress expression of rhesus and human huntingtin, it was first necessary to identify nucleic acid sequences that effectively suppress the expression of human and rhesus HD genes. Towards this goal, a PCR strategy was used to clone and assemble 3437 bp of the 5′ portion of the rhesus HD gene. Briefly, a series of PCR primers predicted to anneal to the rhesus HD cDNA were designed based on evolutionarily conserved sequences identified in an alignment of the human (NM—002111) and pig (AB016793) cDNA sequences. These primers were used to amplify partially overlapping portions of the rhesus HD gene from first strand cDNA prepared from rhesus brain and kidney tissues (BioChain Institute, Inc; C1534035 and C1534142 respectively) using high fidelity DNA polymerases. The recovered PCR products were cloned into pCR-Blunt-TOPO (Invitrogen) and sequenced using standard methods. Sequence alignments between multiple, independently derived clones were analyzed to ensure the elimination of potential PCR and sequencing errors. This sequence information was also used to design additional primers to clone gaps in the recovered HD cDNA sequence. A single composite clone containing 3437 bp of the rhesus HD cDNA was assembled using PCR and conventional cloning techniques.
- Next, potential synthetic nucleic acid suppressor sequences for rhesus monkey huntingtin that correspond with portions of the human sequence (i.e., target genes were rhesus and human HD genes) were identified using online software (http://www.dharmacon.com/) and also obtained from Dharmacon® (Dharmacon Research, Inc., Boulder, Colo.). These nucleic acid sequences included those in the following Table 1:
-
TABLE 1 siRNA sequences Nucleic SEQ Acid Position in ID Sequence human cDNA NO: Name Nucleotide Base Sequence (NM_002111) 1 rh#1-19 TGACAGCAGTGTTGATAAA 2071–2089 2 rh#2-19 AAGAACGAGTGCTCAATAA 2862–2880 3 rh#4-19 TTTATGAACTGACGTTACA 1221–1239 4 rh#5-19 GGAGTATTGTGGAACTTAT 1404–1422 5 rh#6-19 GAGTATTGTGGAACTTATA 1405–1423 6 rh#11-19 AGACCGTGTGAATCATTGT 442–460 7 rh#12-19 GGTTACAGCTCGAGCTCTA 645–663 8 rh#13-19 GGTTTTGTTAAAGGCCTTC 898–916 9 rh#1-27 TGACAGCAGTGTTGATAAATTTGTGTT 2071–2097 10 rh#2-27 AAGAACGAGTGCTCAATAATGTTGTCA 2862–2888 11 rh#4-27 TTTATGAACTGACGTTACATCATACAC 1221–1247 12 rh#5-27 GGAGTATTGTGGAACTTATAGCTGGAG 1404–1430 13 rh#6-27 GAGTATTGTGGAACTTATAGCTGGAGG 1405–1431 14 rh#11-27 AGACCGTGTGAATCATTGTCTGACAAT 442–468 15 rh#13-27 GGTTTTGTTAAAGGCCTTCATAGCGAA 898–924
Note that, as will be understood by one of skill in the art, the nucleic acid molecules of the present invention include the sequences in the preceding table, the reverse complement of these sequences and RNA based sequences including uracils in the place of the listed thymines. Thus, the sequences in the preceding table can be considered target sequences as well as sequences included in the nucleic acid molecules of the present invention. SEQ ID NOS. 1-8 are 19 nucleotide base sequences. SEQ ID NO. 9-15 are the same sequences extended to 27 nucleotide base sequences. The sequence identified as SEQ ID NO. 7 was not extended into a 27 nucleotide base sequence because extending this sequence resulted in a mismatch between the rhesus monkey and human HD sequences. Control sequences also were chosen. The control sequences included a non-sense scrambled control (SEQ ID NO. 19; TAGCGACTAAACACATCAA) and a TNFα sequence (SEQ ID NO. 16; AATCCTCCTTCGTATTATA) both purchased from Dharmacon. - To identify which of the above identified 19 nucleotide nucleic acid sequences most effectively suppressed rhesus monkey huntingtin expression, an in vitro co-transfection assay system was developed. Referring to
FIG. 1 , rhesus monkey HD gene sequences were subcloned into pTracer™-CMV2 (Invitrogen, Corp., Carlsbad, Calif.) to generate pTracer-rhuntingtin (pTRACER-rhHD). The recombinant plasmid also included a GFP-Zeocin reporter gene for transfection efficiency normalization. The CMV promoter directed constitutive expression of the target gene (rhesus monkey HD) while the EF1 promoter directed constitutive expression of the GFP-Zeocin reporter gene. - The generated recombinant plasmids were used to facilitate screening of nucleic acid sequences by co-transfection into a eukaryotic cell line. Specifically, HEK293 cell cultures at 60-70% confluency were co-transfected with the appropriate target plasmid (2 μg/well of a 6-well plate) and test nucleic acid sequences (100 nM) directed against rhesus monkey HD (SEQ ID NO: 1 through SEQ ID NO: 8), TNFα (as a control (SEQ ID NO. 16) or a non-sense scrambled control (SEQ ID NO. 19). Forty-eight hours post-transfection, total cellular RNA was harvested from the cells and used to make cDNA by standard methods. The cDNAs were analyzed for target (HD) and reporter (GFP) gene expression levels using realtime PCR methods. The data was normalized for GFP expression levels to control for variation in transfection efficiency.
-
FIG. 2 shows the results of the rhesus monkey HD transfection studies related to each of the test nucleic acid sequence's ability to suppress rhesus monkey HD mRNA. As measured by realtime PCR, all non-control sequences effectively suppressed expression of the HD gene when compared to mock treated control cells (set at 100% expression). Because the nucleic acid sequences evaluated in the present experiment have complete sequence identity to portions of the human HD gene. sequence, it is reasonable to expect that they also suppress the expression of the human HD gene, thus suppressing production of human huntingtin protein. - Next, the ability of a subset of the 19 nucleotide sequences was evaluated for its ability to suppress expression of the endogenous rhesus HD gene at two different doses, 100 nM and 10 nM. Specifically, 4MBr5 cell line cultures obtained from American Type Culture Collection (“ATCC”) (cells from a rhesus lung cell line) at 70-80% confluency were transfected with test nucleic acid sequences (SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 4; SEQ ID NO: 6; and SEQ ID NO: 7) directed against rhesus HD mRNA at either 100 nM or 10 nM or control sequences (SEQ ID NO: 19 (scrambled) or SEQ ID NO: 16 (off-target TNFα control)) at 100 nM. Forty-eight hours post transfection total cellular RNA was collected from the cells and used to generate cDNA by standard methods. The cDNAs were used to analyze for rhesus HD and control gene expression using realtime PCR methods. A separate realtime PCR reaction was performed to assess the level of rhesus GAPDH expression. All of the expression data was normalized to GAPDH expression to allow the assessment of the efficacy of siNA-mediated knockdown of rhesus HD in the rhesus cell lines. As shown in
FIG. 3 , all sequences directed against rhesus HD mRNA suppressed rhesus HD gene expression at both doses when compared to controls. - Next, an experiment was performed to evaluate the dependence of rhesus HD mRNA suppression on the length and dose of provided nucleic acid sequences. Specifically, 4MBr5 cells were transfected as described above but with 100 nM, 10 nM, 1.0 nM, 0.2 nM or 0.05 nM of SEQ ID NO: 4 (19 nucleotide sequence); 100 nM, 10 nM, 1.0 nM, 0.2 nM or 0.05 nM of SEQ ID NO: 12 (corresponding 27 nucleotide sequence); 100 nM SEQ ID NO: 19 (scrambled) or 100 nM SEQ ID NO: 16 (off-target TNFα control). As shown in
FIG. 4 , all doses of both sequence lengths suppressed rhesus HD gene expression when compared to controls. While all doses were effective in 4MBr5 cells, 100 nM, 10 nM and 1 nM were the most effective doses for suppressing rhesus HD gene expression regardless of sequence length. - A subsequent experiment evaluating the siNA's ability to suppress expression of the endogenous rhesus HD gene also examined the effectiveness of a 27 nucleotide sequence as compared to its previously-evaluated 19 nucleotide sequence counterpart in LLC-MK2 cells. In this experiment, LLC-MK2 cells (a rhesus kidney cell line also obtained from ATCC) at 70-80% confluency were transfected with test nucleic acid sequences (SEQ ID NO: 4 and SEQ ID NO: 12) at one of two doses, 10 nM or 0.2 nM as well as controls (SEQ ID NO: 19 and SEQ ID NO: 16) at 100 nM. Forty-eight hours post transfection total cellular RNA was collected from the cells and used to generate cDNA by standard methods. The cDNAs were used to analyze for rhesus HD and control gene expression using realtime PCR methods. A separate realtime PCR reaction was performed to assess the level of rhesus GAPDH expression. All of the expression data was normalized to GAPDH expression to allow the assessment of the efficacy of siNA-mediated knockdown of rhesus HD in the rhesus cell lines. As shown in
FIG. 5 , all sequences directed against rhesus HD mRNA suppressed rhesus HD gene expression at both doses when compared to controls. - Following the experiment described in the preceding paragraph, an identical experiment was conducted with the exception that an additional lower dose of SEQ ID NOS: 4 and 12 (0.05 nM) was compared against the effectiveness of the 0.2 nM dose and control SEQ ID NO: 19 (100 nM). As shown in
FIG. 6 , all sequences and doses suppressed endogenous rhesus HD gene expression in LLC-MK2 cells. - The effectiveness of different sequence lengths and doses was also compared using SEQ ID NOS: 1 and 9. Following the same procedures used in the two previously described experiments, LLC-MK2 cells were transfected with 100 nM, 10 nM, 1 nM, 0.1 nM or 0.01 nM SEQ ID NO: 1 (19 nucleotide sequence); 10 nM, 1 nM, 0.1 nM or 0.01 nM SEQ ID NO: 9 (corresponding 27 nucleotide sequence); or control SEQ ID NOS: 19 or 16 (100 nM). As shown in
FIG. 7 , all doses of both sequences suppressed endogenous rhesus HD gene expression in LLC-MK2 cells with the 1 nM and higher doses of SEQ ID NOS: 1 and 9 providing the most suppression. In addition, from this experiment the IC50 (inhibitor concentration required for 50% suppression) values for these two siNAs are estimated to be 10 pM and 75 pM respectively. - Next, a subset of the identified siNA sequences was tested for the chosen sequence's ability to suppress expression of the endogenous human HD gene. In this experiment, HeLa cells (obtained from ATCC) at 70-80% confluency were transfected with test nucleic acid sequences (SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 4; SEQ ID NO: 6; or SEQ ID NO: 7) or control (SEQ ID NO: 19) at 100 nM. Forty-eight hours post transfection total cellular RNA was collected from the cells and used to generate cDNA by standard methods. The cDNAs were used to analyze for human HD and control gene expression using realtime PCR methods. A separate realtime PCR reaction was performed to assess the level of human GAPDH expression. All of the expression data was normalized to GAPDH expression to allow the assessment of the efficacy of siNA-mediated knockdown of human HD in the HeLa cell line. As shown in
FIG. 8A , all sequences directed against human HD mRNA suppressed human HD gene expression when compared to controls. - The experiment just described was next repeated using doses of either 1 nM, 0.1 nM or 0.01 nM SEQ ID NOS. 1, 2, 4, 6 or 7 or 100 nM of control SEQ ID NO: 19. As shown in
FIGS. 8B-8D , all doses of each of these SEQ ID NOS. 1, 2, 4, 6 and 7 were effective in suppressing endogenous human HD gene expression in HeLa cells. In only one instance was human HD suppression not observed, SEQ ID NO: 2 at the lowest dose (0.0 nM). - Following the previously described experiments, studies were undertaken to determine whether sequences of the present invention suppress exogenous huntingtin protein expression. In this first protein suppression experiment, suppression of the partial rhesus huntingtin protein expressed from the pTRACER plasmid depicted in
FIG. 1 was measured by western blot analysis. Specifically, LLC-MK2 cells were cotransfected with the pTRACER-rhHD plasmid (2 μg/well of a 6-well plate) and 100 nM of either SEQ ID NO: 19 (control); SEQ ID NO: 1 or SEQ ID NO: 4. Controls in this experiment also consisted of LLC-MK2 cells transfected solely with the pTRACER-rhHD plasmid. Protein was harvested 48 hours post-transfection and was analyzed using western blot analysis. In this analysis, 10 μg of total protein was loaded per well. Rhesus huntingtin protein expression was measured using the Chemicon® International (Temecula, Calif.) huntingtin antibody MAB2168 and β-actin was measured with abcam® (Cambridge, Mass.) antibody 20272-100. To quantify huntingtin protein expression the intensities of the bands for huntingtin and β-actin on the autoradiogram of the western blot were measured by densitometry. Huntingtin protein expression was normalized to β-actin expression. As can be seen inFIG. 9 , both SEQ ID NO: 1 and SEQ ID NO: 4 were effective to suppress exogenous huntingtin protein expression when compared to controls transfected with the pTRACER-rhHD plasmid and SEQ ID NO: 19 or the pTRACER-rhHD plasmid alone. - Next the ability of SEQ ID NO: 1 and SEQ ID NO: 4 to suppress endogenous protein expression was examined in LLC-MK2 cells again using western blot analysis. LLC-MK2 cells were transfected with 100 nM of either SEQ ID NO: 1, SEQ ID NO: 4 or SEQ ID NO: 19. An additional control consisted of extracts from untransfected cells. Protein was harvested and analyzed 48 hours post-transfection with 10 μg of total protein loaded per western blot well. Again, rhesus huntingtin protein expression was measured using the Chemicon® International (Temecula, Calif.) huntingtin antibody MAB2168 and β-actin was measured with abcam® (Cambridge, Mass.) antibody 20272-100. As is evident on the western blot for rhesus huntingtin and β-actin shown in
FIG. 10 both SEQ ID NO: 1 and SEQ ID NO: 4 suppress huntingtin protein expression. To quantify the amount of protein suppression, the level of rhesus huntingtin protein expression was normalized to β-actin expression. To do this the intensities of the bands on the autoradiogram of the western blot (FIG. 10 ) were measured by densitometry. As can be seen inFIG. 11 , SEQ ID NO: 1 and SEQ ID NO: 4 both suppressed endogenous huntingtin protein expression when compared to cells transfected with control SEQ ID NO: 19 or to extract from untransfected cells. - After effective nucleic acid sequences are identified as described above, effective sequences can be formatted into short hairpin nucleic acid (“shNA”) structures.
FIG. 12 shows SEQ ID NO: 4 reformatted and constructed as an anti-huntingtin shNA sequence (SEQ ID NO: 17;FIG. 12A ).FIG. 12 also shows a control shNA sequence (SEQ ID NO: 18;FIG. 12B ). The shNA sequences contain the siNA nucleic acid sequence (boxed sequence shown in black; inFIG. 12A , an originally effective nucleic acid sequence), a nine nucleotide loop (underlined), the reverse complement of the boxed nucleic acid sequence (italicized), and a Pol III terminator sequence (TTTTTT (bolded)). Four partially overlapping synthesized oligonucleotides (−A1, −A3, −A2, and −A4 inFIG. 12A and −B1, −B3, B2 and −B4 inFIG. 12B ) can be used to assemble the shNAs. In two separate reactions, the ⅓ and 2/4 oligonucleotides for each shNA can be annealed. Referring toFIGS. 12A and 12B , the A1 and B1 oligonucleotides include the boxed sequences. The A2 and B2 oligonucleotides include the underlined nine nucleotide loop, the reverse complement of oligonucleotides A1 and B1 respectively, the bolded Pol III terminator sequence (TTTTTT) and the first G of the EcoRI site depicted in these FIGS. The A3 and B3 oligonucleotides ofFIGS. 12A and 12B respectively include the ApaI overhang region, the reverse complement of the boxed A1/B1 sequences, and the reverse complement of the underlined nine nucleotide loop sequence. The A4 and B4 oligonucleotides include the reverse complement of the italicized portion of A2 and B2 respectively and the reverse complement (AAAAAA) of the bolded Pol III terminator sequence. Finally, the A4 and B4 oligonucleotides contain the EcoRI overhang region. ApaI and EcoRI restriction enzyme-compatible ends are included in the shNA structures for directional subcloning into a murine U6 promoter-containing shuttle vector (pSilencer1.0-U6 ; Ambion, Inc., Austin, Tex.;FIG. 15 ). The full-length shNAs (SEQ ID NOS: 17 and 18) then can be cloned into a ApaI/EcoRI-digested pSilencer vector using a three-way ligation reaction. The U6 promoter (murine or human) is used for constitutive high level expression of the nucleic acid sequences. In keeping with the present invention, a human H1 promoter can also be used. One non-limiting example of a shuttle vector containing the human U6 promoter is psiSTRIKE™ hmGFP from Promega Corporation (Madison, Wis.). One non-limiting example of a shuttle vector containing the human H1 promoter is pSilencer 3.0-H1 from Ambion, Inc, (Austin, Tex.). - While this example provides one embodiment of the nucleic acid sequences of the present invention in shNA format and a method for creating them, other configurations and methods also fall within the scope of the present invention. For example, in one embodiment, the loop structure of the shNA hairpin is 4 to 10 nucleotides in length. In another embodiment, the arms of the hairpin structures are less than approximately 30 nucleotides in length. In another embodiment, the arms of the hairpin structure are between 19 and 27 nucleotides in length. Thus, while a specific example is given, this example should not be interpreted to limit the scope of the present invention.
- In the next described experiment, the ability of plasmids expressing shNA to suppress rhesus HD gene expression was examined. LLC-MK2 cells were transfected with a psiSTRIKE™ hmGFP plasmid (Promega Corporation, Madison, Wis.) with one of two stem lengths (SEQ ID NO: 4 (19 nucleotides) or SEQ ID NO: 12 (27 nucleotides)) and one of two different loop structures (EB4 or mir23). A scrambled control was also generated for each of the loop structures. Specifically, these scrambled control sequences included a 27 nucleotide sequence control (SEQ ID NO: 20) for EB4 (
FIG. 13A ) and a 19 nucleotide sequence control (SEQ ID NO: 21) for mir23 (FIG. 13B ; SEQ ID NO: 21 is a modified version of control SEQ ID NO: 18). Thus, the whole of the transfected sequences in this study included SEQ ID NO. 20; SEQ ID NO. 21; SEQ ID NO. 22 (FIG. 13C ; modified SEQ ID NO: 17-EB4 (as will be recognized by one of ordinary skill in the art, SEQ ID NO: 22 includes SEQ ID NO: 17 with modified overhang regions for subcloning into a different vector)); SEQ ID NO: 23 (FIG. 13D ; modified SEQ ID NO: 17-mir23); SEQ ID NO: 24 (FIG. 13E ; shNA-modified SEQ ID NO: 12-EB4); and SEQ ID NO: 25 (FIG. 13F ; shNA-modified SEQ ID NO: 12-mir23). As can be seen inFIG. 14 , all test plasmids suppressed rhesus HD gene expression when compared to control plasmids. - Next, a method to prepare viral production plasmids is described. This method is based on the method for producing the nucleic acid sequences in shNA formats described above. As will be understood by one of skill in the art, however, various known modifications of the described technique also fall within the scope of the present invention. First, the BamHI fragment (
FIG. 15 ) containing the shNA expression cassette (murine U6 promoter, shNA sequence, and Pol III terminator sequence) from each of the pSilencer shuttle vectors (huntingtin and control) is recovered, blunted with T4 DNA polymerase, and subcloned into an AAV1/2 expression vector (deprAVE™; GeneDetect.com Ltd, Bradenton, Fla.). As shown inFIG. 16 , in this example, in the final viral expression vector (used for virus production), the U6 promoter (murine or human) can drive the expression of the shNA and the Woodchuck enhancer/chicken β-actin promoter can drive the expression of the enhanced green fluorescent protein (WPRE/CAG-eGFP). These expression cassettes can be flanked by viral inverted terminal repeats (ITR). The Woodchuck post-transcriptional regulatory element (WPRE) and the presence of a bovine growth hormone (BGH) polyadenlyation sequence ensure high transcription following cellular transduction. In alternative methods of the present invention, the expression cassette additionally contains a polyadenylation signal, such as a synthetic minimal polyadenylation signal. In another alternative embodiment of the present invention, the H1 promoter can be used. -
FIG. 17 depicts a different plasmid, the plasmid used to construct pAAV vectors used in the following experiments to generate AAV (pAAV-hrGFP, Stratagene, La. Jolla, Calif.). Six different plasmids were constructed; 3 with an H1 promoter and 3 with a U6 promoter (human H1 promoter from Ambion (Austin, Tex.) and human U6 promoter from Promega (Madison, Wis.)). Specifically, the following were subcloned into the depicted vector (1) U6-SEQ ID NO: 17; (2) U6-SEQ ID NO: 26 (SEQ ID NO: 26 is SEQ ID NO: 1 in an shRNA format; seeFIG. 18A ); (3) H1-SEQ ID NO: 17; (4) H1-SEQ ID NO: 26; (5) U6-SEQ ID NO: 18 (scrambled shNA control); and (6) H1-SEQ ID NO: 27 (SEQ ID NO: 27 is a scrambled SEQ ID NO: 1 shNA control; seeFIG. 18B ). In this instance this was done by removing a cassette containing the promoter and the shNA sequence from the appropriate psiSTRIKE™ or pSilencer 3.0 shNA expressing vector with PvuII. This PvuII fragment was then subcloned into the blunted MluI site of pAAV-hrGFP (Stratagene, La. Jolla, Calif.). Directionality was confirmed by restriction digest mapping and sequence analysis. - These six pAAV plasmids were co-transfected into HEK293T cells along with pTRACER-rhHD (
FIG. 1 ). As controls, two siRNAs (SEQ ID NOS: 1 or 4) and the non-sense scrambled control (SEQ ID NO: 19) were also transfected into HEK293T cells. pTRACER-rhHD was also transfected alone as a control. RNA was collected 48 hours post transfection and the suppression of rhesus HD gene expression (on the pTRACER plasmid) was measured by realtime PCR and normalized to the amount of GFP expressed from the pTRACER-rhHD plasmid. As can be seen inFIG. 19 , pAAV plasmids containing U6-SEQ ID NO: 17; U6-SEQ ID NO: 26; H1-SEQ ID NO: 17; and H1-SEQ ID NO: 26 were as effective at suppressing exogenous rhesus HD gene expression as previously tested SEQ ID NO: 1 and SEQ ID NO: 4. pAAV plasmids expressing scrambled control sequences did not suppress exogenous rhesus HD gene expression. - Next, the described pAAV plasmids along with the required phelper and REPCAP plasmids were used to generate recombinant adeno-associated virus (AAV) with
serotype 1. Five separate AAV viruses were generated. These viruses were engineered to express U6-SEQ ID NO: 26; U6-SEQ ID NO: 17; H1-SEQ ID NO: 26; U6-SEQ ID NO: 18 (shNA control) or H1-SEQ ID NO: 27 (shNA control). The ability of these viruses to suppress endogenous human HD gene expression in HeLa cells and HEK293T cells was examined. 5*105 cells in a well of a 6-well plate were transduced with 5×109 virions by directly adding the virus to the well of cells in 1 ml of Dulbecco's Modified Eagle Medium (DMEM) cell culture media supplemented with 2% fetal bovine serum (FBS). This plate was incubated at 37° C., 5% CO2 for 2 hours with gentle mixing by rocking every 30 minutes. Following this 2 hour incubation, 1 ml of DMEM cell culture media supplemented with 18% FBS was added to each well yielding a final FBS concentration of 10%. Growth of the transduced cells was continued at 37° C., 5% CO2. RNA was collected 72 hours post transduction and used to make cDNA by standard methods. The cDNAs were analyzed for HD and GAPDH expression levels by realtime PCR methods. Endogenous HD expression was normalized to endogenous GAPDH expression. As shown inFIG. 20 , U6-SEQ ID NO: 26 and U6-SEQ ID NO: 17 were effective at suppressing endogenous human HD gene expression. P values were determined by comparison to the mock transduced data set. In this experiment, even though H1-SEQ ID NO: 26 did not significantly suppress endogenous human HD expression in vitro, its potential effectiveness in vivo should not be discounted especially in light of literature indicating a potential disconnect between in vitro and in vivo activity. See, for example, Wooddell et al., 334 Biochem. and Biophys. Res. Comm. 117-27 (2005). - The siNA sequences and molecules of the present invention can be manipulated to enhance their uptake into the RISC complex. Specifically, manipulating the 3 prime terminal nucleotide of the sense strand can be highly advantageous. Preferential entry of the guide, or antisense, strand into RISC can be achieved by introducing 3 prime mismatches in the sense strand while maintaining perfect base pairing (of the antisense strand and the intended mRNA target) at the 5 prime terminus of the antisense strand. This maximizes entry of the antisense strand into the RISC complex, while also reducing potential off-target inhibition by the sense strand.
- Physical methods to introduce nucleic acid molecules and/or their carriers (i.e. vectors) into eukaryotic cells are known in the art. Some of these methods include, without limitation, calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, lipofection, protoplast fusion, particle bombardment, microinjection, liposome fusion, biolistics and other suitable methods found in, for example, Sambrook, et al. (Molecular Cloning: A Laboratory Manual, 2nd, ed, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals. Further, biological methods to introduce nucleic acid molecules into a cell include the use of viral vectors. For mammalian gene therapy, viral vectors, and especially retroviral vectors, have become the most widely used method for inserting genes into mammalian, e.g., rhesus monkey or human cells. Other viral vectors can be derived from poxviruses, herpes simplex virus I, adenoviruses and adeno-associated viruses, and the like (see, for example, Boenisch et al., U.S. Pat. No. 5,350,674 and Wilson et al., U.S. Pat. No. 5,585,362 which are hereby incorporated by reference). Embodiments of the present invention also can be delivered through the use of liposomes, polyethyleneimine, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. Nucleic acid molecules also can be directly delivered to cells or tissues with or without the aforementioned vehicles. The nucleic acid molecules/vehicle combinations can be locally delivered by catheter and drug pump systems, delivered by direct local injection or through the use of polymers and/or drug-eluting stents.
- The nucleic acid sequences, molecules, expression cassettes and vectors of the present invention can be used to suppress HD gene expression and resulting huntingtin formation. The nucleic acid sequences, molecules, expression cassettes and vectors of the present invention also can be used in the study of HD pathogenesis. Further, the nucleic acid sequences, molecules, expression cassettes and vectors of the present invention also may be administered to prevent or treat the symptoms of HD. When used as a potential treatment, the amount of these agents administered as well as the timing of their delivery will vary depending on various factors including, for example and without limitation, the composition chosen, the weight, physical condition, and age of the patient, and whether prevention or treatment is desired as well as other factors known to skilled practitioners. Administration of the therapeutic agents can be continuous or intermittent. The administration of the agents of the invention can be essentially continuous over a preselected period of time or can be in a series of spaced doses. Further, both local and systemic administration can be appropriate for use within the present invention. Such factors can be determined by the researcher or treating physician.
- A pre-clinical study of the safety of suppressing huntingtin protein expression in the normal adult rhesus monkey brain was conducted. In this study, a 6 year old female rhesus monkey weighing approximately 3.9 kg was anesthetized and bilaterally infused with an anti-HD shRNA/GFP-containing recombinant adeno-associated virus (AAV) (AAV-U6-SEQ ID NO: 17 (serotype AAV1; 2.07×1012 vg/ml; lot #J0531)) by stereotactic injection. Sterotactic targets were determined by presurgical MRI and included putamen (AP=17; L=11; DV1=20 and DV2=17) and caudate nucleus (AP=20.5; L=5.6; DV=17) sites. Injections (Hamilton syringe (100 μl) with 27 Ga needle (compression fitting)) were performed at 2 putamen sites (50 μl/site) using a single needle tract and 1 caudate site (50 μl) at a rate of 1 μl/min. Following this injection, the needle was left in place for at least 20 minutes and then withdrawn at a rate of 1 mm/min.
- Twenty-eight days later, the animal was deeply anesthetized with pentobarbital (1.5 ml intramuscular; 2 ml, intravenous) and transcardially perfused with heparinized ice-cold saline (4-6 L). Following perfusion and removal, the brain was placed into a container of ice-cold saline.
- The right hemisphere of the brain was sectioned into 14-4 mm thick coronal sections and numbered 1-14 (rostral to caudal). A 14G biopsy needle was then used to collected tissue punches from various brain regions. A total of 103 tissue punches was collected from the right hemisphere. Each tissue punch contained about 6 mg of tissue and was snap frozen in liquid nitrogen and stored at −80° C. until RNA was isolated.
-
TABLE 2 Summary of sources of tissue punches Caudate; 20 punches (3 Putamen; 20 punches (3 Nigra, 5 punches (1 slabs) slabs) slab) Accumbens; 8 punches GP; 5 punches (1 slab) Front. cx; 9 (2 slabs) punches (1 s) Cerebellum; 6 punches (1 Occipital cx; 9 punches Motor cx; 9 punches slab) (1 slab) (1 s) Thalamus; 6 punches (1 Hippocampus; 6 punches Total n = 103 slab) (1 slab) punches
RNA was isolated from tissue punches using the RNeasy Lipid Kit from Qiagen (Valencia, Calif.). Total RNA was used to generate cDNA using the Stratascript® First Strand cDNA synthesis kit from Stratagene (La Jolla, Calif.). The cDNAs were used to analyze expression levels of rhesus HD and GAPDH by realtime PCR. In addition, AAV expression was monitored by measuring the level of GFP expression. Rhesus HD expression was normalized to rhesus GAPDH expression and compared to a region not expressing the virus (GFP−). - The left hemisphere of the brain was sectioned into 4 blocks (rostral to caudal).
Block 1 was 10 mm;blocks block 4 was 20 mm. Each block was embedded in OCT, snap frozen in isopentane and stored at −80° C. Ten micron sections were then collected and placed onto laser microdissection (LMD) compatible slides. Tissue on the slides was fixed in ethanol (30 seconds in 75% ethanol; 30 seconds in 95% ethanol; and 30 seconds in 100% ethanol) with an air dry between steps. Slides were then screened to identify the ones containing brain regions of interest (i.e. caudate and putamen) and data on viral spread was obtained by following the expression of the marker gene (GFP). GFP positive regions were collected by LMD from the caudate and putamen. - RNA was isolated from GFP collected material using the PicoPure RNA isolation kit from Arcturus (Mountain View, Calif.). The RNA was quantified prior to the generation of cDNA. Typically about 10-80 ng of total RNA from the LMD collected material was isolated. cDNA was prepared using the Stratascript® QPCR cDNA synthesis kit from Stratagene (La Jolla, Calif.). HD expression was measured by realtime PCR and normalized to GAPDH expression in the same sample. To verify RNA collected from virally transduced cells were being analyzed, GFP realtime PCR to monitor GFP expression was also performed.
- As can be seen in
FIG. 21 , when measured from samples obtained from tissue punches, in vivo HD gene expression was suppressed in the putamen but not the caudate. The likely reason suppression was not observed in the caudate is that the percent of cells expressing the virus within the collected punch is too low to elicit a detectable level of rhesus HD suppression. This was addressed by collecting GFP+ transduced cells by LMD. When measured from samples obtained through LMD, in vivo HD gene expression was suppressed in the putamen, caudate and corona radiate (FIG. 22 ; R1=replicate 1; R2=replicate 2). Together, these data demonstrate the feasibility and safety of in vivo HD gene expression in accordance with the methods and sequences of the present invention. - A pre-clinical study of the safety of suppressing huntingtin protein expression in the normal adult rhesus monkey brain is conducted over a 12-month period. During the first three months of the study, six rhesus macaques (Macaca mulatta) are trained to perform the tasks of a commercially available computerized behavioral test battery (Monkey CANTAB, Model 80650, Lafayette Instruments, Lafayette, Ind.) that is based upon human neuropsychological tests (CANTAB, CeNeS, Cambridge, UK). The performance of these six monkeys on the test battery is compared to previously published performance norms for rhesus monkeys to verify that the monkey's cognitive abilities are within normal limits. See, for example, Weed et al., Brain Research: Cognitive Brain Research, 1999, Oct. 25; 8(3) 185-201.
- Next, the monkeys are randomly assigned to one of two experimental groups: the first group of three monkeys receives intracranial injections of an adeno-associated virus (AAV) vector comprising an expression cassette containing an RNA polymerase III promoter driving expression of a short hairpin RNA transcript encoding for the shNA of SEQ ID NO: 17. A second expression cassette in the same vector encodes for a green fluorescent protein reporter gene. The second group of three monkeys receives intracranial injections of an adeno-associated virus vector comprising an expression cassette containing the same RNA polymerase III promoter driving expression of a control shNA sequence (SEQ ID NO:18). Also, a second expression cassette in this vector encodes for a green fluorescent protein reporter gene. The AAV vector is administered to the caudate nucleus and putamen of each hemisphere of each monkey's brain. The amount of AAV vector administered in each intracranial injection, and the surgical method and procedures for making these injections, are well-known to those skilled in the art.
- After a one-week post-operative recovery time, the monkeys are repeatedly tested on a periodic basis using the Monkey CANTAB computerized testing battery for the remainder of the twelve-month study period. The cognitive and behavioral performance of each monkey over time is compared to its own pre-operative performance. No statistically significant decline in cognitive or behavioral performance measures is obtained for either the monkeys treated with the control shNA vector, or the monkeys treated with the anti-rhesus-HD shNA vector. This indicates that there are no significant cognitive or behavioral consequences of suppressing the expression of huntingtin protein in the caudate and putamen of the adult primate brain. Periodic neurological examinations of each monkey by skilled and qualified veterinarians unaware of the experimental group membership of each monkey also shows no neurological deficits in the monkeys.
- At the end of the twelve-month study period, the monkeys are humanely terminated, and the brain of each monkey is removed and examined for abnormalities by trained pathologists. In addition, it is studied by fluorescence microscopy, immunohistochemistry, and molecular and biochemical assays. The regions of the brain in which the AAV vector effectively delivered the shNA are identified by fluorescence microscopy. This reveals expression of the green fluorescent protein reporter gene in substantial regions of the caudate nucleus and putamen in each hemisphere of each monkey's brain. Immunohistochemical staining for huntingtin protein, using antibodies and methods well-known to those skilled in the art, shows reduced levels of huntingtin protein in the caudate and putamen of the monkeys who received the anti-rhesus-HD shNA vector, compared to the monkeys who received the control shNA vector, indicating suppression of huntingtin protein expression by the shNA of the invention. Finally, homogenized brain tissue samples from the caudate and putamen of each monkey's brain are assayed for levels of rhesus HD mRNA measured by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) assay, and for levels of rhesus huntingtin protein measured by Western blotting, using methods well-known to those skilled in the art. These assays show the expression of HD mRNA and huntingtin protein is significantly reduced in the caudate and putamen of the monkeys who received the anti-rhesus-HD shNA vector, compared to the monkeys who received the control shNA vector. These data further confirm that the shNA vector of the invention suppresses the expression of huntingtin protein in the caudate and putamen of the monkeys receiving the anti-rhesus-HD shNA vector. Because this suppression of huntingtin protein in the caudate and putamen of the rhesus monkeys does not result in corresponding cognitive or behavioral deficits, or other observable neurological abnormalities or brain tissue pathology, the safety of suppressing huntingtin protein in these regions of the adult primate brain is established.
- Once the safety of suppressing huntingtin protein in the caudate and putamen of the adult primate brain is established in rhesus monkeys, the same shNA expression cassette that is used in the pre-clinical safety tests in rhesus monkeys is engineered into an AAV vector using methods well-known to those skilled in the art. This AAV vector comprises an expression cassette containing an RNA polymerase III promoter driving expression of a short hairpin RNA transcript encoding for the shNA of SEQ ID NO: 17. The AAV vector optionally does not contain a second expression cassette encoding for a green fluorescent protein reporter gene, because this expression cassette is not needed for the treatment of HD in patients.
- It is to be especially understood that because the shNA sequence encoded by SEQ ID NO:17 contains the siNA target region of SEQ ID NO: 4, and the sequence of SEQ ID NO: 4 is 100% homologous with corresponding sequences within both the Macaca mulatta and the Homo sapiens HD gene, an AAV vector comprising an expression cassette containing SEQ ID NO: 17 is effective at suppressing the expression of the Homo sapiens HD gene and huntingtin protein, as well as the Macaca mulatta HD gene and huntingtin protein.
- Following safety and dose-escalation trials in human patients in which the safety of administering the AAV vector comprising SEQ ID NO: 17 is established, clinical trials evaluating the clinical efficacy of the invention in treating HD in human patients are conducted. In these trials, the AAV vector can be administered to the human patient's brain according to the systems and methods disclosed in U.S. Patent Application Numbers 20040162255 and 20040220132. These trials establish that suppression of huntingtin protein in the caudate and putamen of human patients afflicted with HD using the nucleic acid molecules, expression cassettes, or vectors of the present invention is effective at arresting and partially reversing the cognitive and motor deficits in patients treated after onset of these symptoms of the disease. These results are consistent with findings obtained in conditional transgenic mouse models of HD, in which expression of a mutant HD transgene results in a disease phenotype, after which suppressing the expression of the mutant HD transgene results in reversal of the disease phenotype and improvement of the mice. Yamamoto et al., Cell, 2000, Mar. 31; 101(1):57-66.
- To verify that the shNA sequences disclosed above are effective in vivo, 3*1011 viral particles comprising AAV vectors including shNAs of SEQ ID. NO: 26 or SEQ. ID. NO: 17 or a control shNA (SEQ. ID. NO: 18) under regulation of the human U6 promoter upstream of GFP sequence under control of CMV promoter were injected into Rhesus moneys as follows:
-
TABLE 3 Experimental design Age, Animal # yrs Hemisphere RNA construct Target 1 6 Left SEQ. ID. NO: 17 Putamen, Caudate Right SEQ. ID. NO: 17 Putamen, Caudate 2 15 Left SEQ. ID. NO: 18 Putamen Right SEQ. ID. NO: 17 Putamen 3 19 Left SEQ. ID. NO: 26 Putamen Right SEQ. ID. NO: 17 Putamen - Huntington (HD) mRNA was quantified by qPCR using total RNA isolated from tissue punches and laser microdissected sections (LMD). Huntingtin protein was quantified by western blot analysis using total protein isolated from tissue punches.
- The injection of a vector comprising shNA of SEQ. ID. NO. 17 resulted in 37% reduction of HD mRNA in the part of putamen expressing GFP in
animal 1, as compared to the part of putamen not expressing GFP in the same (right) hemisphere, as measured by qPCR of RNA isolated from tissue punches. - In the left hemisphere of the same animal, the amount of HD mRNA was decreased by about 65% to 70% in the GFP-expressing areas compared to the areas not expressing GFP, as measured by qPCR of RNA isolated from LMD sections.
- Further, the effect of the shNA treatment was treatment-specific. In
animal 2, significant decrease of HD mRNA was observed in GFP-expressing areas of the right hemisphere (injected with a vector comprising SEQ. ID. NO. 17), as opposed to the GFP-expressing areas of the left hemisphere (injected with a vector comprising control shNA, SEQ. ID. NO: 18). - Thus, these data show that the viral construct comprising shNA of SEQ. ID. NO. 17 can locally and significantly reduce the amount of HD mRNA.
- The animals were injected according to the protocol of the previous example. Histopathological analyses were conducted by analyzing GFP fluorescence, hematoxylin-eosin (H&E) staining, huntingtin immunofluorescent staining, calnexin immunofluorescent staining and protein disulfide isomerase (PDI) immuofluorescent staining. The results of those studies show that HD suppression does not cause any detectable neuro-anatomical abnormalities in the injected areas. Some evidence of perivascular cuffing in virally transduced regions was observed, but this cuffing did not correlate with HD suppression. Further, staining for calnexin and PDI did not reveal any obvious alterations in the endoplasmic reticulum (ER) of the transduced cells.
- The animals were injected according to the protocol of Working Example 1. Spontaneous activity and fine motor activity were also measured by EthnoVision and mMAP equipment, respectively. EthnoVision is a video tracking system that can be used to measure distance traveled, body movement speed and vertical activity. Associated computer software is able to quantify each of these parameters. mMAP (monkey Movement Analysis Panel) was used to objectively measure the time of fine motor movements of the small hand muscles in retrieving food items presented to the test animal.
- HD suppression within the caudate and putamen did not cause alterations in spontaneous activity of the animals. Fine locomotor activity was not impaired in any of the animals. Further, all animals tended to improve in fine motor skills post-virus injection.
- It is to be understood that the present invention is not limited to the particular embodiments, materials, and examples described herein, as these can vary. For example, the nucleic acid molecules of the present invention can be created in a variety of formats and lengths. Indeed, those skilled in the art will recognize that the most important attribute of the nucleic acid molecules of the present invention is their ability to enter the RISC complex and also complementarily bind to the mRNA sequences of interest to induce an RNA interference effect, resulting in reduction of the mRNA stability and/or the translation rate of these sequences. The phrase “complementarily bind” as used herein, refers to the abilities of the nucleic acid molecules to form hydrogen bond(s) with mRNA sequences by either traditional Watson-Crick pairing or other non-traditional types.
- It also is to be understood that the terminology used herein is used for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention. It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include the plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to “a sequence” or “an shNA” is a reference to one or more sequences or shNAs and includes equivalents thereof known to those skilled in the art and so forth.
- Unless defined otherwise, all technical terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Specific methods, devices, and materials are described, although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention.
Claims (39)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/501,634 US7902352B2 (en) | 2005-05-06 | 2006-08-09 | Isolated nucleic acid duplex for reducing huntington gene expression |
PCT/US2007/017638 WO2008021136A2 (en) | 2006-08-09 | 2007-08-08 | Methods and sequences to suppress primate huntington gene expression in vivo |
EP07811178A EP2056881A4 (en) | 2006-08-09 | 2007-08-08 | Methods and sequences to suppress primate huntington gene expression in vivo |
JP2009523833A JP2010500025A (en) | 2006-08-09 | 2007-08-08 | Methods and sequences for suppressing primate Huntington gene expression in vivo |
CNA2007800372445A CN101557831A (en) | 2006-08-09 | 2007-08-08 | Methods and sequences to suppress primate huntington gene expression in vivo |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67872905P | 2005-05-06 | 2005-05-06 | |
US11/429,491 US20060257912A1 (en) | 2005-05-06 | 2006-05-04 | Methods and sequences to suppress primate huntington gene expression |
US11/501,634 US7902352B2 (en) | 2005-05-06 | 2006-08-09 | Isolated nucleic acid duplex for reducing huntington gene expression |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/429,491 Continuation-In-Part US20060257912A1 (en) | 2005-05-06 | 2006-05-04 | Methods and sequences to suppress primate huntington gene expression |
Publications (3)
Publication Number | Publication Date |
---|---|
US20070261126A1 true US20070261126A1 (en) | 2007-11-08 |
US20100325746A9 US20100325746A9 (en) | 2010-12-23 |
US7902352B2 US7902352B2 (en) | 2011-03-08 |
Family
ID=39082580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/501,634 Expired - Fee Related US7902352B2 (en) | 2005-05-06 | 2006-08-09 | Isolated nucleic acid duplex for reducing huntington gene expression |
Country Status (5)
Country | Link |
---|---|
US (1) | US7902352B2 (en) |
EP (1) | EP2056881A4 (en) |
JP (1) | JP2010500025A (en) |
CN (1) | CN101557831A (en) |
WO (1) | WO2008021136A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060257912A1 (en) * | 2005-05-06 | 2006-11-16 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
US20070161591A1 (en) * | 2005-08-18 | 2007-07-12 | University Of Massachusetts | Methods and compositions for treating neurological disease |
US20090118206A1 (en) * | 2003-09-12 | 2009-05-07 | University Of Massachusetts | Rna interference for the treatment of gain-of-function disorders |
US20100151470A1 (en) * | 2007-05-01 | 2010-06-17 | University Of Massachusetts | Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy |
US20110172291A1 (en) * | 2003-09-12 | 2011-07-14 | University Of Massachusetts | Rna interference for the treatment of gain-of-function disorders |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040241854A1 (en) | 2002-08-05 | 2004-12-02 | Davidson Beverly L. | siRNA-mediated gene silencing |
US20050042646A1 (en) * | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
US20080274989A1 (en) * | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
CA2670967C (en) | 2006-11-29 | 2016-05-10 | University Of Iowa Research Foundation | Alternative export pathways for vector expressed rna interference |
US8258286B2 (en) | 2007-04-26 | 2012-09-04 | University Of Iowa Research Foundation | Reduction of off-target RNA interference toxicity |
EP2152874A2 (en) | 2007-04-26 | 2010-02-17 | University of Iowa Research Foundation | Rna interference suppression of neurodegenerative diseases and methods of use thereof |
CN101790385A (en) | 2007-07-12 | 2010-07-28 | 普罗森那技术公司 | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
EP2614827B1 (en) | 2007-10-26 | 2017-06-28 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
JP5507555B2 (en) * | 2008-06-30 | 2014-05-28 | チョ−エー・ファーム・カンパニー・リミテッド | Porcine αS1 casein gene, promoter thereof, and use thereof |
BRPI0923225A2 (en) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | Phosphorus-modified nucleic acid synthesis method |
EP2421971B1 (en) | 2009-04-24 | 2016-07-06 | BioMarin Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
KR101885383B1 (en) | 2009-07-06 | 2018-08-03 | 웨이브 라이프 사이언시스 리미티드 | Novel nucleic acid prodrugs and methods of use thereof |
JP5868324B2 (en) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | Asymmetric auxiliary group |
WO2012109667A1 (en) | 2011-02-12 | 2012-08-16 | University Of Iowa Research Foundation | Therapeutic compounds |
CN103796657B (en) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | The method for synthesizing functionalization nucleic acid |
EP4043039A1 (en) | 2012-01-27 | 2022-08-17 | BioMarin Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
EP4219516A3 (en) | 2012-07-13 | 2024-01-10 | Wave Life Sciences Ltd. | Chiral control |
EP2873674B1 (en) | 2012-07-13 | 2020-05-06 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
WO2015108047A1 (en) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
JPWO2015108048A1 (en) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant and antitumor agent having antitumor activity |
KR102423317B1 (en) | 2014-01-16 | 2022-07-22 | 웨이브 라이프 사이언시스 리미티드 | Chiral design |
CN107075514A (en) | 2014-05-20 | 2017-08-18 | 衣阿华大学研究基金会 | The therapeutic compounds of Huntington's disease |
MX2017010369A (en) | 2015-02-10 | 2017-12-14 | Genzyme Corp | VARIANT RNAi. |
MA43072A (en) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
MA45270A (en) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
US11603529B2 (en) | 2017-09-22 | 2023-03-14 | Genzyme Corporation | Variant RNAi |
KR20230162024A (en) | 2021-03-29 | 2023-11-28 | 알닐람 파마슈티칼스 인코포레이티드 | Huntingtin (HTT) iRNA preparation composition and method of use thereof |
Citations (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4888829A (en) * | 1985-10-21 | 1989-12-26 | Porvair Limited | Gloves |
US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US5236908A (en) * | 1991-06-07 | 1993-08-17 | Gensia Pharmaceuticals, Inc. | Methods of treating injury to the central nervous system |
US5354326A (en) * | 1993-01-27 | 1994-10-11 | Medtronic, Inc. | Screening cable connector for interface to implanted lead |
US5534350A (en) * | 1994-12-28 | 1996-07-09 | Liou; Derlin | Powerfree glove and its making method |
US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US5639275A (en) * | 1993-08-12 | 1997-06-17 | Cytotherapeutics, Inc. | Delivery of biologically active molecules using cells contained in biocompatible immunoisolatory capsules |
US5702716A (en) * | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5720720A (en) * | 1993-08-27 | 1998-02-24 | The United States Of America As Represented By The Department Of Health And Human Services | Convection-enhanced drug delivery |
US5735814A (en) * | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
US5782892A (en) * | 1997-04-25 | 1998-07-21 | Medtronic, Inc. | Medical lead adaptor for external medical device |
US5800390A (en) * | 1991-05-24 | 1998-09-01 | Sumitomo Pharmaceuticals Company, Limited | Equipment for intracerebral administration of preparations |
US5840059A (en) * | 1995-06-07 | 1998-11-24 | Cardiogenesis Corporation | Therapeutic and diagnostic agent delivery |
US5849995A (en) * | 1993-09-27 | 1998-12-15 | The University Of British Columbia | Mouse model for Huntington's Disease and related DNA sequences |
US5882561A (en) * | 1996-11-22 | 1999-03-16 | Drexel University | Process for making a dense ceramic workpiece |
US5925310A (en) * | 1996-03-29 | 1999-07-20 | Asahi Glass Company Ltd. | Method of making a silicon carbide product |
US5942455A (en) * | 1995-11-14 | 1999-08-24 | Drexel University | Synthesis of 312 phases and composites thereof |
US5968059A (en) * | 1997-03-06 | 1999-10-19 | Scimed Life Systems, Inc. | Transmyocardial revascularization catheter and method |
US6042579A (en) * | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US6093180A (en) * | 1995-04-28 | 2000-07-25 | Medtronic, Inc. | Intraparenchymal infusion catheter system |
US6110459A (en) * | 1997-05-28 | 2000-08-29 | Mickle; Donald A. G. | Transplants for myocardial scars and methods and cellular preparations |
US6151525A (en) * | 1997-11-07 | 2000-11-21 | Medtronic, Inc. | Method and system for myocardial identifier repair |
US6180613B1 (en) * | 1994-04-13 | 2001-01-30 | The Rockefeller University | AAV-mediated delivery of DNA to cells of the nervous system |
US6187906B1 (en) * | 1997-08-11 | 2001-02-13 | Aukland Uniservices Limited | Methods to improve neural outcome |
US6231969B1 (en) * | 1997-08-11 | 2001-05-15 | Drexel University | Corrosion, oxidation and/or wear-resistant coatings |
US6245884B1 (en) * | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
US6281009B1 (en) * | 1996-09-11 | 2001-08-28 | The General Hospital Corporation | Use of a non-mammalian DNA virus to express an exogenous gene in a mammalian cell |
US6291243B1 (en) * | 1999-04-28 | 2001-09-18 | The Board Of Trustees Of The Leland Stanford Jr. University | P element derived vector and methods for its use |
US6294202B1 (en) * | 1994-10-06 | 2001-09-25 | Genzyme Corporation | Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers |
US20010027309A1 (en) * | 1996-04-30 | 2001-10-04 | Medtronic, Inc. | Therapeutic method for treatment of alzheimer's disease |
US6300539B1 (en) * | 1997-03-27 | 2001-10-09 | Medical Research Council | Model for chronic cerebral inflammation by intracerebral injection of double stranded RNA |
US20010031947A1 (en) * | 1996-04-30 | 2001-10-18 | Eric R. Waldkoetter | Method and apparatus for drug infusion |
US6309634B1 (en) * | 1998-05-27 | 2001-10-30 | Avigen, Inc. | Methods of treating Parkinson's disease using recombinant adeno-associated vector (rAAV) |
US6310048B1 (en) * | 1999-12-09 | 2001-10-30 | St. Louis University | Antisense modulation of amyloid beta protein expression |
US6313268B1 (en) * | 1998-10-16 | 2001-11-06 | Vivian Y. H. Hook | Secretases related to Alzheimer's dementia |
US6319905B1 (en) * | 1998-12-29 | 2001-11-20 | Cell Genesys, Inc. | Method of controlling L-Dopa production and of treating dopamine deficiency |
US20020004038A1 (en) * | 1996-04-30 | 2002-01-10 | Baugh Robert F. | Autologous platelet gel spray delivery system |
US6343233B1 (en) * | 1997-04-25 | 2002-01-29 | Medtronic, Inc. | Medical lead adaptor |
US6372250B1 (en) * | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
US6372721B1 (en) * | 1993-12-17 | 2002-04-16 | Spinal Cord Society | Method for inducing DNA synthesis in neurons |
US6376471B1 (en) * | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
US20020068093A1 (en) * | 2000-08-30 | 2002-06-06 | Biocoat Incorporated | Bi-laminar, hyaluronan coatings with silver- based anti-microbial properties |
US6436708B1 (en) * | 1997-04-17 | 2002-08-20 | Paola Leone | Delivery system for gene therapy to the brain |
US6436392B1 (en) * | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
US20020114780A1 (en) * | 2000-11-30 | 2002-08-22 | Krys Bankiewicz | Methods of increasing distribution of therapeutic agents |
US6461989B1 (en) * | 1999-12-22 | 2002-10-08 | Drexel University | Process for forming 312 phase materials and process for sintering the same |
US6468524B1 (en) * | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
US6551290B1 (en) * | 2000-03-31 | 2003-04-22 | Medtronic, Inc. | Catheter for target specific drug delivery |
US20030078229A1 (en) * | 2000-05-31 | 2003-04-24 | Copernicus Therapeutics, Inc. | Lyophilizable and enhanced compacted nucleic acids |
US20030088236A1 (en) * | 1999-03-18 | 2003-05-08 | Johnson Randolph Mellus | Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners |
US20030092003A1 (en) * | 1999-12-29 | 2003-05-15 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of Alzheimer's disease |
US20030095958A1 (en) * | 2001-04-27 | 2003-05-22 | Bhisetti Govinda R. | Inhibitors of bace |
US20030109476A1 (en) * | 2001-08-07 | 2003-06-12 | Kmiec Eric B. | Compositions and methods for the prevention and treatment of Huntington's disease |
US20030120282A1 (en) * | 2001-12-24 | 2003-06-26 | Scouten Charles W. | Stereotaxic manipulator with retrofitted linear scales and digital display device |
US20030143732A1 (en) * | 2001-04-05 | 2003-07-31 | Kathy Fosnaugh | RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA |
US20030152947A1 (en) * | 2001-06-15 | 2003-08-14 | Crossman David C. | Methods for detecting and treating the early onset of aging-related conditions |
US6609020B2 (en) * | 1999-12-01 | 2003-08-19 | Steven Gill | Neurosurgical guide device |
US20030175772A1 (en) * | 2001-12-27 | 2003-09-18 | Jiwu Wang | Compositions for DNA mediated gene silencing |
US20030190635A1 (en) * | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
US6632671B2 (en) * | 2000-02-28 | 2003-10-14 | Genesegues, Inc. | Nanoparticle encapsulation system and method |
US20040018520A1 (en) * | 2002-04-22 | 2004-01-29 | James Thompson | Trans-splicing enzymatic nucleic acid mediated biopharmaceutical and protein |
US20040023390A1 (en) * | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
US20040023855A1 (en) * | 2002-04-08 | 2004-02-05 | John Constance M. | Biologic modulations with nanoparticles |
US20040028390A9 (en) * | 2001-11-09 | 2004-02-12 | David Chatenever | Replaceable hardware component of a camera control unit for video systems |
US20040186422A1 (en) * | 2003-03-20 | 2004-09-23 | Robert Rioux | Devices and methods for delivering therapeutic or diagnostic agents |
US20040215164A1 (en) * | 2002-02-20 | 2004-10-28 | Abbott Chun Lim | Methods of treating abnormal biological conditions using metal oxides |
US20040220132A1 (en) * | 2002-11-26 | 2004-11-04 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US20050032733A1 (en) * | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
US20050042646A1 (en) * | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
US20050048641A1 (en) * | 2002-11-26 | 2005-03-03 | Medtronic, Inc. | System and method for delivering polynucleotides to the central nervous system |
US6870030B2 (en) * | 1997-01-28 | 2005-03-22 | Smithkline Beecham Corporation | Asp2 |
US20050096284A1 (en) * | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US20050106731A1 (en) * | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
US20050137134A1 (en) * | 2003-02-24 | 2005-06-23 | North Bristol N.H.S. Trust | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
US20050153353A1 (en) * | 2004-01-09 | 2005-07-14 | Bernd Meibohm | Real-time polymerase chain reaction-based genotyping assay for beta2-adrenergic receptor single nucleotide polymorphism |
US20050191638A1 (en) * | 2002-02-20 | 2005-09-01 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US20050202075A1 (en) * | 2004-03-12 | 2005-09-15 | Pardridge William M. | Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers |
US6945969B1 (en) * | 2000-03-31 | 2005-09-20 | Medtronic, Inc. | Catheter for target specific drug delivery |
US20050209179A1 (en) * | 2000-08-30 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
US20050255086A1 (en) * | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
US20060014165A1 (en) * | 2003-07-14 | 2006-01-19 | Decode Genetics Ehf. | Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association |
US20060041242A1 (en) * | 2001-10-31 | 2006-02-23 | Medtronic, Inc. | System and method of treating stuttering by neuromodulation |
US20060150747A1 (en) * | 2002-07-19 | 2006-07-13 | Phluid, Inc. | Infusion pump and method for use |
US20060210538A1 (en) * | 2004-10-22 | 2006-09-21 | Neurologix, Inc. | Use of apotosis inhibiting compounds in degenerative neurological disorders |
US20060224411A1 (en) * | 2005-04-01 | 2006-10-05 | Sheng-Yen Chang | Method of constructing and using a memorial |
US20060257912A1 (en) * | 2005-05-06 | 2006-11-16 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
US20070031844A1 (en) * | 2002-11-14 | 2007-02-08 | Anastasia Khvorova | Functional and hyperfunctional siRNA |
US20070184029A1 (en) * | 2003-12-29 | 2007-08-09 | Am Biosolutions | Method of treating cancer using platelet releasate |
US7320965B2 (en) * | 2005-10-28 | 2008-01-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Huntingtin gene |
US20080113351A1 (en) * | 2004-05-11 | 2008-05-15 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
US20090022864A1 (en) * | 2005-01-27 | 2009-01-22 | Vincent Jan Steenhof | Method for preparing a beverage suitable for consumption from at least two ingredients to be dissolved and/or extracted and an amount of liquid |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7069634B1 (en) | 1995-04-28 | 2006-07-04 | Medtronic, Inc. | Method for manufacturing a catheter |
US20050282198A1 (en) | 1997-05-29 | 2005-12-22 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype |
DE19938960A1 (en) | 1998-03-10 | 2001-02-22 | Bisping Hans Juergen | Test cable connecting probe to test apparatus, e.g. for testing implanted pacemaker, electrotherapy or electro-diagnostics includes crocodile clip and flexible conductor with spring contact |
US6659995B1 (en) | 2000-11-17 | 2003-12-09 | Syde A. Taheri | Autologous myocyte micro granual retrieval and implantation (AMMGRI) |
CZ302719B6 (en) | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Isolated double-stranded RNA molecule, process for its preparation and use |
US7182944B2 (en) | 2001-04-25 | 2007-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of increasing distribution of nucleic acids |
US20050282188A1 (en) | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
US20050277133A1 (en) | 2001-05-18 | 2005-12-15 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US20030224512A1 (en) | 2002-05-31 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of beta-site APP-cleaving enzyme expression |
EP1552749B1 (en) | 2002-07-25 | 2013-03-27 | Nissei Kabushiki Kaisha | Rolled cone manufacturing apparatus |
US20040241854A1 (en) | 2002-08-05 | 2004-12-02 | Davidson Beverly L. | siRNA-mediated gene silencing |
US20040265849A1 (en) | 2002-11-22 | 2004-12-30 | Applera Corporation | Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof |
US7605249B2 (en) * | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
JP2004232811A (en) | 2003-01-31 | 2004-08-19 | Hitachi Unisia Automotive Ltd | Electromagnetic clutch for driving auxiliary machine |
US20040186528A1 (en) | 2003-03-20 | 2004-09-23 | Medtronic, Inc. | Subcutaneous implantable medical devices with anti-microbial agents for chronic release |
US20040198640A1 (en) | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
PL1620133T3 (en) | 2003-05-01 | 2016-05-31 | Genzyme Corp | Gene therapy for neurometabolic disorders |
US20040258666A1 (en) | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
US7917228B2 (en) | 2003-05-13 | 2011-03-29 | Medtronic, Inc. | Medical lead adaptor assembly |
AU2004239114B2 (en) | 2003-05-14 | 2008-03-13 | Japan Science And Technology Agency | Inhibition of the expression of huntingtin gene |
WO2005027980A1 (en) | 2003-09-12 | 2005-03-31 | University Of Massachusetts | Rna interference for the treatment of gain-of-function disorders |
US7498316B2 (en) | 2004-04-06 | 2009-03-03 | University Of Massachusetts | Methods and compositions for treating gain-of-function disorders using RNA interference |
EP1735443A2 (en) | 2004-04-14 | 2006-12-27 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2006022639A1 (en) | 2004-07-21 | 2006-03-02 | Applera Corporation | Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof |
US20080280843A1 (en) | 2006-05-24 | 2008-11-13 | Van Bilsen Paul | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
GB0520235D0 (en) | 2005-10-05 | 2005-11-16 | Astrazeneca Ab | Method |
AR059036A1 (en) | 2006-01-17 | 2008-03-12 | Schering Corp | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS |
US20080039415A1 (en) | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
CN200970210Y (en) | 2006-10-12 | 2007-11-07 | 王会才 | Cleaning and dewatering machine for mop |
-
2006
- 2006-08-09 US US11/501,634 patent/US7902352B2/en not_active Expired - Fee Related
-
2007
- 2007-08-08 WO PCT/US2007/017638 patent/WO2008021136A2/en active Application Filing
- 2007-08-08 JP JP2009523833A patent/JP2010500025A/en active Pending
- 2007-08-08 CN CNA2007800372445A patent/CN101557831A/en active Pending
- 2007-08-08 EP EP07811178A patent/EP2056881A4/en not_active Withdrawn
Patent Citations (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683202B1 (en) * | 1985-03-28 | 1990-11-27 | Cetus Corp | |
US4888829A (en) * | 1985-10-21 | 1989-12-26 | Porvair Limited | Gloves |
US4683195B1 (en) * | 1986-01-30 | 1990-11-27 | Cetus Corp | |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US5702716A (en) * | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5800390A (en) * | 1991-05-24 | 1998-09-01 | Sumitomo Pharmaceuticals Company, Limited | Equipment for intracerebral administration of preparations |
US5236908A (en) * | 1991-06-07 | 1993-08-17 | Gensia Pharmaceuticals, Inc. | Methods of treating injury to the central nervous system |
US5354326A (en) * | 1993-01-27 | 1994-10-11 | Medtronic, Inc. | Screening cable connector for interface to implanted lead |
US5639275A (en) * | 1993-08-12 | 1997-06-17 | Cytotherapeutics, Inc. | Delivery of biologically active molecules using cells contained in biocompatible immunoisolatory capsules |
US5720720A (en) * | 1993-08-27 | 1998-02-24 | The United States Of America As Represented By The Department Of Health And Human Services | Convection-enhanced drug delivery |
US5849995A (en) * | 1993-09-27 | 1998-12-15 | The University Of British Columbia | Mouse model for Huntington's Disease and related DNA sequences |
US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US6372721B1 (en) * | 1993-12-17 | 2002-04-16 | Spinal Cord Society | Method for inducing DNA synthesis in neurons |
US6180613B1 (en) * | 1994-04-13 | 2001-01-30 | The Rockefeller University | AAV-mediated delivery of DNA to cells of the nervous system |
US6294202B1 (en) * | 1994-10-06 | 2001-09-25 | Genzyme Corporation | Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers |
US5534350A (en) * | 1994-12-28 | 1996-07-09 | Liou; Derlin | Powerfree glove and its making method |
US6093180A (en) * | 1995-04-28 | 2000-07-25 | Medtronic, Inc. | Intraparenchymal infusion catheter system |
US5997525A (en) * | 1995-06-07 | 1999-12-07 | Cardiogenesis Corporation | Therapeutic and diagnostic agent delivery |
US5840059A (en) * | 1995-06-07 | 1998-11-24 | Cardiogenesis Corporation | Therapeutic and diagnostic agent delivery |
US5942455A (en) * | 1995-11-14 | 1999-08-24 | Drexel University | Synthesis of 312 phases and composites thereof |
US5925310A (en) * | 1996-03-29 | 1999-07-20 | Asahi Glass Company Ltd. | Method of making a silicon carbide product |
US20010031947A1 (en) * | 1996-04-30 | 2001-10-18 | Eric R. Waldkoetter | Method and apparatus for drug infusion |
US20010027309A1 (en) * | 1996-04-30 | 2001-10-04 | Medtronic, Inc. | Therapeutic method for treatment of alzheimer's disease |
US20020004038A1 (en) * | 1996-04-30 | 2002-01-10 | Baugh Robert F. | Autologous platelet gel spray delivery system |
US5814014A (en) * | 1996-04-30 | 1998-09-29 | Medtronic Incorporated | Techniques of treating neurodegenerative disorders by brain infusion |
US5735814A (en) * | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
US6281009B1 (en) * | 1996-09-11 | 2001-08-28 | The General Hospital Corporation | Use of a non-mammalian DNA virus to express an exogenous gene in a mammalian cell |
US5882561A (en) * | 1996-11-22 | 1999-03-16 | Drexel University | Process for making a dense ceramic workpiece |
US6870030B2 (en) * | 1997-01-28 | 2005-03-22 | Smithkline Beecham Corporation | Asp2 |
US5968059A (en) * | 1997-03-06 | 1999-10-19 | Scimed Life Systems, Inc. | Transmyocardial revascularization catheter and method |
US6300539B1 (en) * | 1997-03-27 | 2001-10-09 | Medical Research Council | Model for chronic cerebral inflammation by intracerebral injection of double stranded RNA |
US6436708B1 (en) * | 1997-04-17 | 2002-08-20 | Paola Leone | Delivery system for gene therapy to the brain |
US5782892A (en) * | 1997-04-25 | 1998-07-21 | Medtronic, Inc. | Medical lead adaptor for external medical device |
US6343233B1 (en) * | 1997-04-25 | 2002-01-29 | Medtronic, Inc. | Medical lead adaptor |
US6042579A (en) * | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US6110459A (en) * | 1997-05-28 | 2000-08-29 | Mickle; Donald A. G. | Transplants for myocardial scars and methods and cellular preparations |
US6231969B1 (en) * | 1997-08-11 | 2001-05-15 | Drexel University | Corrosion, oxidation and/or wear-resistant coatings |
US6187906B1 (en) * | 1997-08-11 | 2001-02-13 | Aukland Uniservices Limited | Methods to improve neural outcome |
US6376471B1 (en) * | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
US6151525A (en) * | 1997-11-07 | 2000-11-21 | Medtronic, Inc. | Method and system for myocardial identifier repair |
US6436392B1 (en) * | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
US6309634B1 (en) * | 1998-05-27 | 2001-10-30 | Avigen, Inc. | Methods of treating Parkinson's disease using recombinant adeno-associated vector (rAAV) |
US20050180955A1 (en) * | 1998-05-27 | 2005-08-18 | Regents Of The University Of California | Methods of treating parkinson's disease using viral vectors |
US20020141980A1 (en) * | 1998-05-27 | 2002-10-03 | The Regents Of The University Of California | Convection-enhanced delivery of AAV vectors |
US6245884B1 (en) * | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
US6313268B1 (en) * | 1998-10-16 | 2001-11-06 | Vivian Y. H. Hook | Secretases related to Alzheimer's dementia |
US6319905B1 (en) * | 1998-12-29 | 2001-11-20 | Cell Genesys, Inc. | Method of controlling L-Dopa production and of treating dopamine deficiency |
US20030088236A1 (en) * | 1999-03-18 | 2003-05-08 | Johnson Randolph Mellus | Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners |
US6291243B1 (en) * | 1999-04-28 | 2001-09-18 | The Board Of Trustees Of The Leland Stanford Jr. University | P element derived vector and methods for its use |
US6609020B2 (en) * | 1999-12-01 | 2003-08-19 | Steven Gill | Neurosurgical guide device |
US6310048B1 (en) * | 1999-12-09 | 2001-10-30 | St. Louis University | Antisense modulation of amyloid beta protein expression |
US6461989B1 (en) * | 1999-12-22 | 2002-10-08 | Drexel University | Process for forming 312 phase materials and process for sintering the same |
US20030092003A1 (en) * | 1999-12-29 | 2003-05-15 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of Alzheimer's disease |
US6632671B2 (en) * | 2000-02-28 | 2003-10-14 | Genesegues, Inc. | Nanoparticle encapsulation system and method |
US6468524B1 (en) * | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
US6945969B1 (en) * | 2000-03-31 | 2005-09-20 | Medtronic, Inc. | Catheter for target specific drug delivery |
US6551290B1 (en) * | 2000-03-31 | 2003-04-22 | Medtronic, Inc. | Catheter for target specific drug delivery |
US6372250B1 (en) * | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
US20030078229A1 (en) * | 2000-05-31 | 2003-04-24 | Copernicus Therapeutics, Inc. | Lyophilizable and enhanced compacted nucleic acids |
US20050209179A1 (en) * | 2000-08-30 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
US20020068093A1 (en) * | 2000-08-30 | 2002-06-06 | Biocoat Incorporated | Bi-laminar, hyaluronan coatings with silver- based anti-microbial properties |
US20020114780A1 (en) * | 2000-11-30 | 2002-08-22 | Krys Bankiewicz | Methods of increasing distribution of therapeutic agents |
US20030143732A1 (en) * | 2001-04-05 | 2003-07-31 | Kathy Fosnaugh | RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA |
US20030095958A1 (en) * | 2001-04-27 | 2003-05-22 | Bhisetti Govinda R. | Inhibitors of bace |
US20050032733A1 (en) * | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
US20030152947A1 (en) * | 2001-06-15 | 2003-08-14 | Crossman David C. | Methods for detecting and treating the early onset of aging-related conditions |
US20030109476A1 (en) * | 2001-08-07 | 2003-06-12 | Kmiec Eric B. | Compositions and methods for the prevention and treatment of Huntington's disease |
US20060041242A1 (en) * | 2001-10-31 | 2006-02-23 | Medtronic, Inc. | System and method of treating stuttering by neuromodulation |
US20040028390A9 (en) * | 2001-11-09 | 2004-02-12 | David Chatenever | Replaceable hardware component of a camera control unit for video systems |
US20030120282A1 (en) * | 2001-12-24 | 2003-06-26 | Scouten Charles W. | Stereotaxic manipulator with retrofitted linear scales and digital display device |
US20030175772A1 (en) * | 2001-12-27 | 2003-09-18 | Jiwu Wang | Compositions for DNA mediated gene silencing |
US20040215164A1 (en) * | 2002-02-20 | 2004-10-28 | Abbott Chun Lim | Methods of treating abnormal biological conditions using metal oxides |
US20030190635A1 (en) * | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
US20050096284A1 (en) * | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US20050191638A1 (en) * | 2002-02-20 | 2005-09-01 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US20040023855A1 (en) * | 2002-04-08 | 2004-02-05 | John Constance M. | Biologic modulations with nanoparticles |
US20040018520A1 (en) * | 2002-04-22 | 2004-01-29 | James Thompson | Trans-splicing enzymatic nucleic acid mediated biopharmaceutical and protein |
US20060150747A1 (en) * | 2002-07-19 | 2006-07-13 | Phluid, Inc. | Infusion pump and method for use |
US20040023390A1 (en) * | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
US20050106731A1 (en) * | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
US20050042646A1 (en) * | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
US20050255086A1 (en) * | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
US20060009408A1 (en) * | 2002-08-05 | 2006-01-12 | University Of Iowa Research Foundation, A Iowa Corporation | siRNA-Mediated gene silencing with viral vectors |
US20070031844A1 (en) * | 2002-11-14 | 2007-02-08 | Anastasia Khvorova | Functional and hyperfunctional siRNA |
US20050048641A1 (en) * | 2002-11-26 | 2005-03-03 | Medtronic, Inc. | System and method for delivering polynucleotides to the central nervous system |
US20040220132A1 (en) * | 2002-11-26 | 2004-11-04 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US20050137134A1 (en) * | 2003-02-24 | 2005-06-23 | North Bristol N.H.S. Trust | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
US20040186422A1 (en) * | 2003-03-20 | 2004-09-23 | Robert Rioux | Devices and methods for delivering therapeutic or diagnostic agents |
US20060014165A1 (en) * | 2003-07-14 | 2006-01-19 | Decode Genetics Ehf. | Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association |
US20070184029A1 (en) * | 2003-12-29 | 2007-08-09 | Am Biosolutions | Method of treating cancer using platelet releasate |
US20050153353A1 (en) * | 2004-01-09 | 2005-07-14 | Bernd Meibohm | Real-time polymerase chain reaction-based genotyping assay for beta2-adrenergic receptor single nucleotide polymorphism |
US20050202075A1 (en) * | 2004-03-12 | 2005-09-15 | Pardridge William M. | Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers |
US20080113351A1 (en) * | 2004-05-11 | 2008-05-15 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
US20060210538A1 (en) * | 2004-10-22 | 2006-09-21 | Neurologix, Inc. | Use of apotosis inhibiting compounds in degenerative neurological disorders |
US20090022864A1 (en) * | 2005-01-27 | 2009-01-22 | Vincent Jan Steenhof | Method for preparing a beverage suitable for consumption from at least two ingredients to be dissolved and/or extracted and an amount of liquid |
US20060224411A1 (en) * | 2005-04-01 | 2006-10-05 | Sheng-Yen Chang | Method of constructing and using a memorial |
US20060257912A1 (en) * | 2005-05-06 | 2006-11-16 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
US7320965B2 (en) * | 2005-10-28 | 2008-01-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Huntingtin gene |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9434943B2 (en) | 2003-09-12 | 2016-09-06 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
US20090118206A1 (en) * | 2003-09-12 | 2009-05-07 | University Of Massachusetts | Rna interference for the treatment of gain-of-function disorders |
US7947658B2 (en) | 2003-09-12 | 2011-05-24 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
US20110172291A1 (en) * | 2003-09-12 | 2011-07-14 | University Of Massachusetts | Rna interference for the treatment of gain-of-function disorders |
US8680063B2 (en) | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
US10344277B2 (en) | 2003-09-12 | 2019-07-09 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
US11299734B2 (en) | 2003-09-12 | 2022-04-12 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
US8258112B2 (en) | 2005-05-06 | 2012-09-04 | Medtronic, Inc | Methods and sequences to suppress primate huntington gene Expression |
US20060257912A1 (en) * | 2005-05-06 | 2006-11-16 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
US20070161591A1 (en) * | 2005-08-18 | 2007-07-12 | University Of Massachusetts | Methods and compositions for treating neurological disease |
US20100267810A1 (en) * | 2005-08-18 | 2010-10-21 | University Of Massachusetts | Methods and compositions for treating neurological disease |
US9914924B2 (en) | 2005-08-18 | 2018-03-13 | University Of Massachusetts | Methods and compositions for treating neurological disease |
US20100151470A1 (en) * | 2007-05-01 | 2010-06-17 | University Of Massachusetts | Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy |
Also Published As
Publication number | Publication date |
---|---|
WO2008021136A3 (en) | 2008-07-03 |
US20100325746A9 (en) | 2010-12-23 |
WO2008021136B1 (en) | 2008-08-07 |
EP2056881A2 (en) | 2009-05-13 |
WO2008021136A2 (en) | 2008-02-21 |
EP2056881A4 (en) | 2010-10-20 |
CN101557831A (en) | 2009-10-14 |
US7902352B2 (en) | 2011-03-08 |
JP2010500025A (en) | 2010-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7902352B2 (en) | Isolated nucleic acid duplex for reducing huntington gene expression | |
US8557975B2 (en) | Methods and sequences to suppress primate Huntington gene expression | |
RU2711147C2 (en) | Therapeutic compounds for treating huntington's disease | |
TWI657819B (en) | Compositions for modulating tau expression | |
JP6395058B2 (en) | Composition and use thereof for huntingtin | |
Rodríguez-Lebrón et al. | Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice | |
JP6072842B2 (en) | Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by suppression of natural antisense transcripts against BDNF | |
WO2007002904A2 (en) | Methods and sequences to preferentially suppress expression of mutated huntingtin | |
AU2023237125A1 (en) | Allele-specific silencing therapy for Dynamin 2-related diseases | |
US20100120900A1 (en) | Methods And Sequences To Preferentially Suppress Expression of Mutated Huntingtin | |
JP6919098B2 (en) | Modulation of microRNAs for myotonic dystrophy type 1 and microRNA antagonists for that purpose | |
US20220010314A1 (en) | Rnai induced reduction of ataxin-3 for the treatment of spinocerebellar ataxia type 3 | |
JP2008517629A (en) | Compositions and methods for short interfering nucleic acid inhibition of Nav1.8 | |
Rochat et al. | Astrocyte‐targeting RNA interference against mutated superoxide dismutase 1 induces motoneuron plasticity and protects fast‐fatigable motor units in a mouse model of amyotrophic lateral sclerosis | |
JP2019513395A (en) | Reagent for the treatment of oropharyngeal muscular dystrophy (OPMD) and its use | |
US20220364091A1 (en) | Compositions and methods for reprogramming age-restricted non-neuronal cells | |
RU2817702C2 (en) | New method of treating retinitis pigmentosa | |
Rochat et al. | Expression of a miRNA targeting mutated SOD1 in astrocytes induces motoneuron plasticity and improves neuromuscular function in ALS mice | |
WO2024036343A2 (en) | Synergistic nucleic acid based therapeutics and methods of use for treating genetic disorders | |
WO2021016061A2 (en) | Inhibitors of microrna 451a for treatment of endometriosis | |
WO2007113784A2 (en) | Methods for modulating the levels and effects of thyrotropin-releasing hormone (trh) and trh-related petides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MEDTRONIC, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KAEMMERER, WILLIAM F.;KAYTOR, MICHAEL D.;REEL/FRAME:018456/0967 Effective date: 20061023 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20230308 |